

CHINA PHARMA HOLDINGS, INC.
Form SB-2/A
April 03, 2007

As filed with the Securities and Exchange Commission on April 3, 2007

Registration No.333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Amendment No. 1 to
FORM SB-2

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

China Pharma Holdings, Inc.
(Exact name of registrant as specified in its charter)

Delaware	73-1564807
(State or other jurisdiction of organization)	(I.R.S. Employer Incorporation or Identification Number)

4953
(Primary Standard Industrial
Classification Code Number)

2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China
Telephone: 86-898-66811730 (China)
(Address and telephone number of principal executive offices)

(Former address and telephone number of principal executive offices)

Copies to:

Charles Law
King and Wood LLP
650 Page Mill Road
Palo Alto, CA 94304

Approximate date of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. [X]

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act Registration Statement number of the earlier effective Registration Statement for the same offering. []

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act Registration Statement number of the earlier effective Registration Statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act Registration Statement number of the earlier effective Registration Statement for the same offering.

If delivery of the Prospectus is expected to be made pursuant to Rule 434, check the following box.

2

CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered	Amount to be registered	Proposed maximum offering price per unit (1)	Proposed maximum aggregate offering price	Amount registered
Common Stock, \$.001 par value (2)	2,505,882 Shares	\$1.80	\$4,510,587.60	\$
Common Stock, \$.0001 par value (3)	1,252,941 shares	\$1.80	\$2,255,293.80	
Total	3,758,823 Shares	\$1.80	\$6,765,881.40	\$

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

- (1) Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) and Rule 457(g) under the Securities Act of 1933, as amended. The average of the high and low price per share of the Registrant's common stock on the Over the Counter Bulletin Board as of March 27, 2007 was \$1.80 per share.
- (2) Represents currently outstanding shares of the registrant's common stock, \$0.001 par value per share, which may be offered pursuant to this registration statement.
- (3) Represents shares of common stock issuable upon exercise of warrants at a price equal to \$2.38 per share.

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. WE MAYNOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES, AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.

SUBJECT TO COMPLETION, DATED April 3, 2007

China Pharma Holdings, Inc.

3

3,758,823 Shares of Common Stock

This Prospectus is an offering of 3,758,823 shares of our common stock, including 1,252,941 shares of common stock issuable upon exercise of outstanding warrants.

These securities are more fully described in the section of this Prospectus titled "Description of Securities."

These securities are being registered to permit public secondary trading of the securities offered by the selling stockholders named in this Prospectus. We will not receive any of the proceeds from the sale of the securities by the selling stockholders.

The selling stockholders may, but are not obligated to, offer all or part of their shares of common stock for resale from time to time through public or private transactions, at either prevailing market prices or at privately negotiated prices. See "Plan of Distribution."

Our common stock is currently quoted on the Over-the-Counter Bulletin Board

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

("OTCBB") under the symbol "CPHI.OB". On March 29, 2007, the last reported sale price on our common stock was \$1.93 per share.

INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD PURCHASE OUR SECURITIES ONLY IF YOU CAN AFFORD A COMPLETE LOSS OF YOUR INVESTMENT. SEE "RISK FACTORS" BEGINNING AT PAGE 12.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this Prospectus is [], 2007

4

China Pharma Holdings, Inc.

TABLE OF CONTENTS

	Page
Prospectus Summary	6
Risk Factors	12
Use of Proceeds	29
Market for Common Equity and Related Stockholder Matters	30
Management's Discussion and Analysis or Plan of Operation	30
Business	41
Management	49
Director and Executive Compensation	50
Certain Relationships and Related Transactions	52
Security Ownership of Certain Beneficial Owners and Management	52
Selling Security Holders	53
Description of Securities	56
Plan of Distribution	58
Legal Matters	59
Experts	59
Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	59
Where You Can Find Additional Information	59
Financial Statements	F1-F17

Funalin, Fukexing, Helpson, HPS logo, Beisha, Shiduotai, Xinuo and other logos are trademarks or logos of Hainan Helpson Bio-pharmaceutical Co., Ltd. ("Helpson"), our indirect wholly-owned subsidiary. All other brand names or trademarks appearing in this Prospectus are the property of their respective holders.

You may only rely on the information contained in this Prospectus in deciding whether to purchase the securities. We have not authorized anyone to provide information different from that contained in this Prospectus. The information contained in the Prospectus is accurate only as of the date of this Prospectus,

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

regardless of the time of delivery of this Prospectus or of any sale of securities. Our business, financial condition, results of operations, and prospects may have changed since that date.

The information contained in this Prospectus is not complete and is subject to change. The selling stockholders are not permitted to sell securities until the registration statement filed with the Securities and Exchange Commission is effective. This Prospectus is not an offer to sell these securities, nor is it a solicitation of an offer to buy these securities in any state where the offer or sale is not permitted.

5

PROSPECTUS SUMMARY

This summary highlights selected information about China Pharma Holdings, Inc., its direct and indirect wholly-owned subsidiaries, and the offering that is contained elsewhere in this Prospectus. You should read the entire Prospectus before making an investment decision, especially the information presented under the heading "Risk Factors" on page 12 and the financial statements and related notes included elsewhere in this Prospectus, as well as any other documents to which we refer you. Except as otherwise indicated by context, references in this Prospectus to "we," "us," "our" or the "Company" are to the combined business of China Pharma Holdings, Inc. and Onny Investment Limited ("Onny"), Helpson, and in each case do not include the selling stockholders. References to "China" or to the "PRC" are references to the People's Republic of China. This Prospectus contains forward-looking statements and information about us. (See "Forward-Looking Statements" on page 29.)

OUR COMPANY

Overview

China Pharma Holdings, Inc. (formerly, TS Electronics, Inc. and prior thereto, Softstone, Inc.) was incorporated on January 28, 1999, pursuant to the provisions of the General Corporation Act of the State of Delaware. On May 31, 1999, we merged with Soft Stone Building Products, Inc., an Oklahoma corporation that was a predecessor to our Company's business. Our initial business operations were conducted at 620 Dallas Drive, Denton TX, 76205. On February 1, 2000, we moved our offices and facilities to Ardmore, OK. In June 2002, we moved our office facilities to Pottsboro, TX. On August 13, 2003, we changed our name to TS Electronics, Inc. On March 15, 2006, we changed our name from TS Electronics, Inc. to China Pharma Holdings, Inc.

Our focus initially was solely on realizing the commercial benefits of a process developed and patented by our first president, Frederick Parker. This process converted waste tires into useful products. We were not successful in promoting this business, wrote off all assets associated with the business and shifted our attention to the commercial possibilities of a then, newly discovered devulcanization process to which we acquired a 5.5 year exclusive license for the Western Hemisphere. In addition, we entered into the business of importing hard-to-find and specialty crumb rubber. We were also not successful in these endeavors and have abandoned all efforts regarding these pursuits.

Effective August 11, 2004, the Company entered into a Stock Exchange Agreement with Hou Xiao, the sole stockholder of China ESCO Holdings Limited ("China ESCO"), a company organized in the Hong Kong Special Administration Region in

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

the People's Republic of China (the "PRC") and its wholly owned operating subsidiary, AsiaNet PE Systems Limited. China ESCO was engaged in the development and manufacturing of electrical energy saving systems and products in the PRC.

6

The consummation of the transaction with China ESCO was subject to a number of conditions, including receipt by us of financial statements of China ESCO as required under applicable regulations, and satisfaction of all applicable regulatory requirements. In January 2005, we declared China ESCO to be in material breach of the agreement and rescinded the agreement.

Effective February 8, 2005, we executed a Letter of Intent with Osage Energy Company, LLC ("Osage") whereby Osage would acquire 90% of the equity interests of the Company. This transaction was never consummated by the parties. The Company had no operations or significant assets from the quarter ended December 31, 2004 until May 2005.

On May 11, 2005, we sold to Halter Financial Group, Inc., in a private placement, 1,875,045 shares of common stock at a purchase price of \$0.1066641 per share, pursuant to the terms of a Stock Purchase Agreement (the "Purchase Agreement"). The private placement was exempt from the registration requirements of the Securities Act, in reliance upon Section 4(2) thereunder. As a result of the purchase, Halter Financial Group, Inc. became our controlling stockholder, owning approximately 75% of our issued and outstanding shares of common stock.

Immediately subsequent to, and as a result of, the closing of the transactions contemplated by the Purchase Agreement, Gene F. Boyd, Keith P. Boyd, Fredrick W. Parker and Leo G. Templer resigned as officers and directors, as applicable, of the Company. Timothy P. Halter was concurrently appointed as a member of the Board of Directors, and Mr. Halter was elected as President, Chief Accounting Officer and Secretary of the Company.

On October 19, 2005 we entered into a Securities Exchange Agreement (the "Exchange Agreement") with Onny Investment Limited, a British Virgin Islands company, and its original stockholders pursuant to which we acquired all of the issued and outstanding shares of Onny from said stockholders in exchange for 27,499,940 shares of our common stock. Upon the closing of the exchange transaction (the "Exchange Transaction"), Onny became the wholly owned subsidiary of our Company. The Exchange Agreement also provides that, upon the effectiveness of an amendment to the Company's Certificate of Incorporation to increase its authorized capital stock, the Company shall issue to Heung Mei Tsui, the principal stockholder of Onny, an additional 4,723,056 shares of common stock (the "Post Closing Shares") to which she would otherwise have been entitled if the Company had enough authorized shares as of the closing of the Exchange Transaction.

Immediately prior to the closing of the Exchange Transaction, Onny completed a private placement (the "Onny Offering") of its convertible preferred stock to 46 accredited investors. The Onny Offering raised gross proceeds of \$5,000,000. Additionally, immediately prior to the Exchange Transaction, participants in the Onny Offering exchanged their preferred shares for an aggregate of 10,000 shares of Onny's common stock. Participants in the Onny Offering then participated in the Exchange Transaction by exchanging such 10,000 shares of common stock for 6,944,619 shares of our common stock.

On March 15, 2006, the Company amended its Certificate of Incorporation to

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

increase its authorized capital stock from 30,000,000 to 60,000,000 shares and filed the Information Statement in accordance with Section 14 of the Exchange

7

Act. On May 16, 2006, the Company issued to Heung Mei Tsui an additional 4,723,056 shares of common stock as provided in the Exchange Agreement. Upon the issuance of the Post Closing Shares, Ms. Tsui holds 25,278,385 shares or approximately 72.8% of the issued and outstanding common stock of the Company.

On July 24, 2006, Zhilin Li, Heung Mei Tsui and the Company entered into that certain Stock Transfer Agreement, as amended on November 24, 2006, pursuant to which Heung Mei Tsui transferred 10,000,000 shares of her personal holdings of the Company's common stock to Zhilin Li in exchange for a sublicense to a patent held by a third party, which was licensed to Ms. Li, which is now licensed to Ms. Tsui. After the aforementioned stock transfer, Ms. Tsui holds 15,278,385 shares or 44% of the total outstanding shares of our common stock. Ms. Li holds 10,000,000 shares or 28.8% of the total outstanding shares of our common stock.

On February 1, 2007, we completed an offering pursuant to a Subscription and Registration Rights Agreement with 17 accredited investors (the "Investors") in connection with a private placement of 2,505,882 shares of the Company's common stock at \$1.7 per share (the "Second Round Financing"). Pursuant to the Agreement, the Investors also received three-year warrants to purchase an aggregate of 1,252,941 shares of Company's common stock at \$2.38 per share. Pursuant to the transaction on February 1, 2007, we received the subscription proceeds in the aggregate amount of \$4,259,900. The net proceeds, after deduction of related expenses, amounted to \$3,814,642.

Prior to the closing of the offering, there were 34,723,056 shares of common stock issued and outstanding. Upon the closing of the Second Round Financing and issuance of an aggregate of 2,505,882 shares to the Investors, there were 37,228,938 shares of common stock issued and outstanding. At the date of the closing, the closing price of the Company's common stock as quoted on the OTCBB was \$2.2.

Onny

Onny Investment Limited ("Onny") was incorporated on January 12, 2005 under the laws of the British Virgin Islands. At the time of incorporation, Onny's authorized capital was \$50,000 and there were 50,000 shares of one class and one series of capital stock, \$1.00 par value, issued and outstanding. Heung Mei Tsui was, at the time of incorporation, the sole stockholder and director of Onny. On July 6, 2005, Onny adopted a sole stockholder's resolution and a sole director's resolution that resolved to change Onny's authorized capital to \$50,000 divided into 4,000,000 ordinary shares of capital stock, \$0.01 par value, and 100 preferred shares of capital stock, \$100 par value. On August 18, 2005, Onny increased its authorized capital to \$5,000,000 divided into 40,000 ordinary shares of capital stock, \$100.00 par value, and 10,000 preferred shares, \$100.00 par value. As of the date of this Prospectus, there are 39,700 ordinary shares issued and outstanding, all of which are held by the Company. No preferred shares of Onny are currently issued and outstanding.

On May 25, 2005, Onny acquired all the equity interests in Hainan Helpson Medicine and Bio-Technology Co. Ltd. in exchange for the assumption of obligations to make cash payments to the Helpson shareholders in the form of common stock dividends from Helpson of \$4,154,041, the assumption of \$4,646,409

of other liabilities and the issuance of non-interest bearing promissory notes totaling \$3,413,265 payable three months after Helpson obtains a business license in the PRC as a wholly foreign owned entity. Effective as of June 21, 2005, Onny became the sole stockholder of Helpson, and Helpson became a wholly foreign-owned enterprise as defined by PRC law.

On October 19, 2005, Onny completed the Onny Offering. Under the terms of the Onny Offering, Heung Mei Tsui agreed to escrow 6,944,611 shares of the Company's common stock that she received as a result of the Exchange Transaction. These shares represent 20% of the Company's issued and outstanding common stock immediately following the closing of the Exchange Transaction (the "Make Good Shares"), so that in the event that actual net income set forth in the consolidated financial statements of the Company for the fiscal year ending December 31, 2006 ("NI") does not reflect \$8 million of net income (the "Guaranteed NI"), the Make Good Shares can be distributed on a pro rata basis to the participants of the Onny Offering in accordance with the following formula:

$$\text{Make Good Shares} = ((\text{Guaranteed NI} - \text{NI}) / \$8\text{m}) \times \text{Make Good Pool}$$

If required, the Make Good Shares will be delivered to participants in the Onny Offering within ten (10) business days of the date the audit report for the period is filed with the SEC.

Additionally, in connection with the Onny Offering, Heung Mei Tsui escrowed 277,785 shares of the Company's common stock that she received as a result of the Exchange Transaction, which shares represent 0.8% of the Company's issued and outstanding common stock immediately following the closing of the Exchange Transaction (the "HFG Make Good Pool"), so that in the event the Company does not achieve the Guaranteed NI, the HFG Make Good Shares will be distributed to HFG International, Limited, an affiliate of Halter Financial Group, Inc., in accordance with the following formula:

$$\text{HFG Make Good Shares} = ((\text{Guaranteed NI} - \text{NI}) / \$8\text{m}) \times \text{HFG Make Good Pool}$$

If required, the HFG Make Good Shares will be delivered within ten (10) business days of the date the audit report for the period is filed with the SEC.

According to the audited consolidated financial statement of Company for the fiscal year ending December 31, 2006, the net income was \$8,587,086 which is more than the Guaranteed NI. Therefore, 7,222,396 shares of Company's common stock which was escrowed shall be revert back to Heung Mei Tsui. As of the date of this Prospectus, Heung Mei Tsui holds 15,278,385 shares or 41.04% of the total outstanding shares of our common stock.

Helpson

Hainan Helpson Medicine and Bio-Technology Co. Ltd. ("Helpson") is a foreign-invested enterprise established in Haikou, Hainan Province, PRC on February 25, 1993. Initially, its name was Hainan Fulin Biomedical Co., Ltd. and it changed to "Helpson" in 1999. The company was originally an "equity joint venture" as defined by China's laws on foreign invested enterprises. The two

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

joint venturers were Haikou Biomedical Engineering Co., Ltd. ("Haikou Biomedical"), a PRC company, and Hong Kong Fudao Development Co., Ltd. ("Fudao"), a Hong Kong company. Haikou Biomedical invested RMB 2,100,000 for a 70% share of Helpson, and Fudao invested \$150,000 for a 30% share of Helpson.

On June 16, 2001, Fudao entered into an Equity Interest Transfer Agreement with Hainan Kaidi Science and Technology Co., Ltd., a PRC company ("Kaidi"). In accordance with the Equity Interest Transfer Agreement, Fudao transferred all of its 30% capital contribution in Helpson to Kaidi in consideration of RMB 2,780,000. As a result of the transfer, Haikou Biomedical continued to hold a 70% equity interest in Helpson, while Kaidi had a 30% equity interest in Helpson. Therefore, Helpson became a PRC domestic company, rather than a foreign-invested company.

Effective on December 26, 2003, Helpson issued new capital stock to Chengdu Huineng Biomedical Co., Ltd. ("Chengdu Bio") and Chongqing Chemical Medicine Holding Group ("Chongqing Chemical"). Chengdu Bio contributed RMB 3,000,000 for a 10.71% equity interest in Helpson and an additional RMB 3,000,000 for Helpson's capital common reserve fund, and Chongqing Chemical contributed RMB 5,000,000 for a 17.86% equity interest in Helpson and an additional RMB 5,000,000 for Helpson's capital common reserve fund. After the issuance of shares, Helpson had four equity holders: Haikou Biomedical, a 50% equity interest; Kaidi, a 21.43% interest; Chengdu Bio, a 10.71% interest; and Chongqing Chemical, a 17.86% interest.

On March 8, 2005, Chongqing Chemical entered into an equity interest transfer agreement with Haikou Biomedical to transfer all of its equity interest in Helpson to Haikou Biomedical. Upon completion of the transfer, there remained only three equity holders of Helpson: Haikou Biomedical, which held a 67.86% equity interest; Kaidi, which held a 21.43% equity interest, and Chengdu Bio, which held a 10.71% equity interest.

As set forth above, on May 25, 2005, Haikou Biomedical, Kaidi and Chengdu Bio entered into an equity interest transfer agreement with Onny to transfer all their equity interests in Helpson to Onny. Effective as of June 21, 2005, Onny became the sole stockholder of Helpson, and Helpson became a wholly foreign-owned enterprise as defined by PRC law.

Upon the closing of the Exchange Transaction on October 19, 2005, we acquired all of the issued and outstanding shares of Onny in exchange for 27,499,940 shares of our common stock and became Onny's sole stockholder. As a result, as of October 19, 2005, Helpson became our wholly owned subsidiary.

As of July 4, 2006, Helpson increased its registered capital from RMB 28,000,000 to RMB 60,000,000 and changed its registered address from Unit 8, D Area, Office Hall, Haikou Bonded Zone, Haikou, Hainan Province, China to C09-2, Haikou Bonded Zone, Haikou, Hainan Province, PRC.

Since its establishment, Helpson has positioned itself in the research, development, manufacturing, and sales of a series of bio-pharmaceutical products. Helpson's products focus primarily on genetic engineering,

bioengineering and peptidergic medicine, as well as chemical medicinal products.

Our principal executive office is located at 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, PRC.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

THE OFFERING

Common stock outstanding before the offering 37,228,938 shares

Common stock offered by the selling stockholders 3,758,823 shares, which includes 1,252,941 shares issuable upon exercise of outstanding warrants.

Use of Proceeds We will not receive any proceeds from the sale of the common stock hereunder. We will receive the sale price of any common stock we sell to the selling stockholders upon exercise of warrants. We intend to use such proceeds, if any, for working capital and general corporate purposes.

OTCBB Trading Symbol CPHI.OB

AN INVESTMENT IN OUR COMMON STOCK IS HIGHLY SPECULATIVE AND INVOLVES A HIGH DEGREE OF RISK. SEE RISK FACTORS BEGINNING ON PAGE 12.

11

RISK FACTORS

The securities being offered hereby are highly speculative, and prospective investors should carefully consider, among others, the following factors related to our business, operations and financial position, in addition to the other information in this Prospectus:

RISKS RELATED TO OUR BUSINESS AND INDUSTRY

WE MAY NEED TO RAISE ADDITIONAL CAPITAL WITHIN THE NEXT TWELVE MONTHS TO FUND OUR OPERATIONS AND FAILURE TO RAISE ADDITIONAL CAPITAL MAY FORCE US TO DELAY, REDUCE, OR ELIMINATE OUR PRODUCT DEVELOPMENT PROGRAMS

Due to the large amount of funds required for research and development and the subsequent marketing of products, the pharmaceutical industry is very capital intensive. The industry is characterized by large and slow receivable turnovers, which signifies that we will need more working capital as our revenues increase. We have traditionally been committed to biomedical R&D, and are now developing traditional chemical medicines within specific market segments such as those of anti-flu and anti-infection. It is likely that we will need to raise additional capital within the next twelve months. Additional capital may be needed for the development of new products or product lines, financing of general and administrative expenses, licensing or acquisition of additional technologies, and marketing of new or existing products. There are no assurances that we will be able to raise the appropriate amount of capital needed for our future operations. Failure to obtain funding when needed may force us to delay, reduce, or eliminate our product development programs and have a material adverse effect on our profitability.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

WE RELY ON A FEW SUPPLIERS AND ANY DISRUPTION WITH OUR SUPPLIERS COULD DELAY PRODUCT SHIPMENTS AND MATERIALLY ADVERSELY AFFECT OUR BUSINESS OPERATIONS AND PROFITABILITY

We have developed relationships with a single or limited number of suppliers for materials that are otherwise generally available. Purchases from our largest supplier, Hainan Xinxin Biotechnology Company, as of December 31, 2006, accounted for approximately 44.42% of the total purchases of our Company. Purchases from our second-to-largest supplier, Sichuang Chengxin Pharmaceutical Company, December 31, 2006, accounted for approximately 33.65% of our total purchases. Although we believe that alternative suppliers are available to supply materials, should either of these suppliers terminate their business arrangements with us or increase their prices of materials supplied, it could delay product shipments and materially adversely affect our business operations and profitability.

IF ALL OR A SIGNIFICANT PORTION OF OUR TRADE RECEIVABLES ARE NOT COLLECTED OR COLLECTION IS DELAYED, OUR NET INCOME WILL DECREASE AND OUR PROFITABILITY WILL BE MATERIALLY ADVERSELY AFFECTED

Our Company had trade receivables, net of allowance for doubtful accounts, of

12

approximately \$5,709,762 (\$1,412,353 for doubtful accounts) and \$12,101,979 (\$1,562,494 for doubtful accounts) as of December 31, 2005 and 2006, respectively. During the years ending December 31, 2005 and 2006, our customers' turnover periods were approximately 116 days and 199, respectively.

It is usual commercial practice that certain customers may repay their debts beyond credit periods granted or may repay slowly when transaction volume increases. There is no assurance that our trade receivables will be fully repaid on a timely basis. The percentage of a trade receivable that is deemed doubtful is as follows: 100% after 720 days; 50 % after 360 days; and 7.5% up to 360 days.

If all or a significant portion of our customers with trade receivables fail to pay all or part of the trade receivables or delay the payment due to us for whatever reason, our net profit will decrease and our profitability will be materially adversely affected.

WE MAY UNDERTAKE ACQUISITIONS IN THE FUTURE, AND ANY DIFFICULTIES IN INTEGRATING THESE ACQUISITIONS MAY DAMAGE OUR PROFITABILITY

In the future, we may acquire additional businesses or products that complement our existing business and expand our business scale. The integration of new businesses and products may prove to be an expensive and time consuming procedure. We can offer no assurance that we will be able to successfully integrate the newly acquired businesses and products or operate the acquired business in a profitable manner. Failure to locate an appropriate acquisition target or failure to successfully integrate and operate acquired businesses and products may materially adversely impact our operations and profits.

THE FAILURE TO MANAGE GROWTH EFFECTIVELY COULD HAVE AN ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION, AND RESULTS OF OUR OPERATIONS

The rapid market growth of our pharmaceutical products may require our Company

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

to expand our employee base for managerial, operational, financial, and other purposes. As of December 31, 2006, we had 123 regular employees. The continued future growth will impose significant added responsibilities upon the members of management to identify, recruit, maintain, integrate, and motivate new employees. Aside from increased difficulties in the management of human resources, we may also encounter working capital issues, as we need increased liquidity to finance the purchases of raw materials and supplies, research and development of new products, acquisition of new businesses and technologies, and the hiring of additional employees. For effective growth management, we will be required to continue improving our operations, management, and financial systems and control. Our failure to manage growth effectively may lead to operational and financial inefficiencies that will have a negative effect on the Company's profitability.

WE ARE DEPENDENT ON CERTAIN KEY PERSONNEL AND LOSS OF THESE KEY PERSONNEL COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS

13

Our Company's success is, to a certain extent, attributable to the management, sales and marketing, and pharmaceutical factory operational expertise of key personnel. Zhilin Li, Heqi Cai, and Yao Huang perform key functions in the operation of our Company. Ms. Li entered into an Employment Agreement with Helpson, which provides that she shall act as its CEO. The term of her Employment Agreement is from July 1, 2005, to June 30, 2010. Mr. Cai entered into an Employment Agreement with Helpson to act as its Director of Development Department for a term from July 1, 2005, to June 30, 2010. Ms. Huang entered into an Employment Agreement with Helpson to act as its Head of Pharmaceutical Plant for a term from July 1, 2005, to June 30, 2010. There can be no assurance that we will be able to retain these officers after the term of their employment or after their contracts expire. The loss of officers could have a material adverse effect upon our business, financial condition, and results of operations. We must attract, recruit and retain a sizeable workforce of technically competent employees. Our ability to effectively implement our business strategy will depend upon, among other factors, the successful recruitment and retention of additional highly skilled, experienced management and other key personnel. We cannot assure that we will be able to hire or retain such employees.

IF WE FAIL TO DEVELOP NEW PRODUCTS WITH HIGH PROFIT MARGINS AND OUR HIGH PROFIT MARGIN PRODUCTS ARE REPLACED BY COMPETITOR'S PRODUCTS, THEN OUR GROSS AND NET PROFIT MARGINS WILL BE ADVERSELY AFFECTED

In the years ended December 31, 2005 and 2006, the gross profit margin for our Company was 51.9% and 46.2% respectively. However, there is no assurance that we will be able to sustain such profit margins in the future. The pharmaceutical market in the PRC is very competitive, and there may be pressure to reduce sale prices of products without a corresponding decrease in the price of raw materials. To the extent that we fail to develop new products with high profit margins and our high profit margin products are substituted by competitors' products, gross profit margins will be adversely affected.

WE FACE COMPETITION IN THE PHARMACEUTICAL MARKET IN THE PRC AND SUCH COMPETITION COULD CAUSE OUR SALES REVENUE AND PROFITS TO DECLINE

According to the State Food and Drug Administration of China (the "SFDA"), there were approximately 5,071 pharmaceutical manufacturing companies in the PRC as of the end of June 2004, of which approximately 3,237 manufacturers obtained certificates of Good Manufacturing Practices certification ("GMP

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

certification"). After GMP certification became a mandatory requirement on July 1, 2004, approximately 1,834 pharmaceutical manufacturers were forced to cease production. Only the 3,237 pharmaceutical manufacturers with GMP certifications may continue their manufacturing operations. The certificates, permits, and licenses required for pharmaceutical operation in the PRC create a potentially significant barrier for new competitors seeking entrance into the market. Despite these obstacles, we face competitors that will attempt to create, or are already marketing, products in the PRC that are similar to ours. There can be no

14

assurance that our products will be either more effective in their therapeutic abilities and/or be able to compete in price with that of our competitors. Failure to do either of these may result in decreased profits for our Company.

OUR SUCCESS IS HIGHLY DEPENDENT ON CONTINUALLY DEVELOPING NEW AND ADVANCED PRODUCTS, TECHNOLOGIES, AND PROCESSES AND FAILURE TO DO SO MAY CAUSE US TO LOSE OUR COMPETITIVENESS IN THE PHARMACEUTICAL INDUSTRY AND MAY CAUSE OUR PROFITS TO DECLINE

To remain competitive in the pharmaceutical industry, it is important to continually develop new and advanced products, technologies and processes. There is no assurance that our competitors' new products, technologies and processes will not render our Company's existing products obsolete or non-competitive. Our Company's competitiveness in the pharmaceutical market therefore relies upon our ability to enhance our current products, introduce new products, and develop and implement new technologies and processes. Our Company's failure to technologically evolve and/or develop new or enhanced products may cause us to lose our competitiveness in the pharmaceutical industry and may cause our profits to decline.

THE COMMERCIAL SUCCESS OF OUR PRODUCTS DEPENDS UPON THE DEGREE OF MARKET ACCEPTANCE AMONG THE MEDICAL COMMUNITY AND FAILURE TO ATTAIN MARKET ACCEPTANCE AMONG THE MEDICAL COMMUNITY MAY HAVE AN ADVERSE IMPACT ON OUR OPERATIONS AND PROFITABILITY

The commercial success of our products depends upon the degree of market acceptance among the medical community. Even if our products are approved by the SFDA, there is no assurance that physicians will prescribe or recommend our products to patients. Furthermore, a product's prevalence and use at hospitals may be contingent upon our relationship with the medical community. The acceptance of our products among the medical community may depend upon several factors including, but not limited to, the product's acceptance by physicians and patients as a safe and effective treatment, cost effectiveness, potential advantages over alternative treatments, and the prevalence and severity of side effects. Failure to attain market acceptance among the medical community may have an adverse impact on our operations and profitability.

THE DISCONTINUATION OF ANY PREFERENTIAL TAX TREATMENTS OR OTHER INCENTIVES CURRENTLY AVAILABLE TO US IN THE PRC COULD MATERIALLY AND ADVERSELY AFFECT OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Pursuant to the Income Tax Law of the PRC for Enterprises with Foreign Investment and Foreign Enterprises promulgated in April, 1991 (the "Income Tax Law"), a foreign invested enterprise as defined under PRC laws shall pay 30% corporate income tax and 3% local income tax. Pursuant to the State Council's Regulations on Encouraging Investment in and Development of Hainan Island promulgated in May, 1988, the corporate income tax for all companies

incorporated in Hainan Province is reduced to 15%. As a foreign invested company incorporated in Hainan Province, currently, Helpson's corporate income tax liability is 15%. Pursuant to the Regulations on Foreign Investment in Hainan

15

Special Economic Zone promulgated by Hainan Province in March, 1991 (the "Regulation on Foreign Investment"), all foreign invested enterprises incorporated in Hainan Province are exempted from paying the local income tax, which normally is 3% of the taxable income. Therefore, Helpson is completely exempted from paying any local income tax. Thus, the corporate income tax liability of Helpson is 15%.

According to the stipulation of Income Tax Law and Regulation on Foreign Investment, an enterprise with foreign investment of a production nature scheduled to operate for a period of not less than ten years shall, from the year of making profits, be exempt from corporate income tax in the first and second years and allowed a fifty percent reduction in the third to fifth years. Helpson has obtained the approval for preferential corporate income tax treatment from Hainan State Administration of Taxation at the end of 2006 and has began to enjoy the preferential tax treatment. Therefore, Helpson shall be exempted from corporate income tax in the first and second years after it begins to make profit. Because the corporate income tax for all companies incorporated in Hainan province is reduced to 15% from the normal corporate income tax rate of 30%, Helpson, from the third to the fifth year after it begins to make profit, shall pay corporate income tax at the rate of half of 15%, or 7.5%.

However, on March 16, 2007, China's national congress approved Income Tax Law of the PRC for Enterprises ("New Income Tax Law"), which will be implemented on January 1, 2008. The New Income Tax Law unifies the enterprise income tax rate, cost deduction and tax incentive policies for both domestic and foreign invested enterprises. This new unified income tax law will increase tax rates on foreign invested enterprises and lower Chinese enterprises' rates to 25%. For current foreign invested enterprise, like us, the applicable tax rate will be moved up to 25% over a five-year grandfather period. We expect the measures to implement this grandfather period to be enacted by the PRC government in the coming months and we will make an assessment of what the impact of the New Income Tax Law is expected to be in the grandfather period. The discontinuation of any such special or preferential tax treatment or other incentives could have an adverse affect our business, financial condition and results of operations.

WE MAY BE SUBJECT TO THE PRC'S PRICE CONTROL OF DRUGS WHICH MAY LIMIT OUR PROFITABILITY AND EVEN CAUSE US TO STOP MANUFACTURING CERTAIN PRODUCTS

The State Development and Reform Commission ("SDRC") of the PRC and the price administration bureaus of the relevant provinces of the PRC in which the pharmaceutical products are manufactured are responsible for the retail price control over our pharmaceutical products. The SDRC sets the price ceilings for certain pharmaceutical products in the PRC. Although our products have not been subject to such price controls as of the date of this Prospectus, there is no assurance that our products will remain unaffected by it. Where our products are subject to a price ceiling, we will need to adjust the product price to meet the requirement and to accommodate for the pricing of competitors in the competition for market shares. The price ceilings set by the SDRC may limit our profitability, and in some instances, such as where the price ceiling is below production costs, may cause us to stop manufacturing certain products which may adversely affect our results of operations.

OUR CERTIFICATES, PERMITS, AND LICENSES ARE SUBJECT TO GOVERNMENTAL CONTROL AND RENEWAL, AND THE FAILURE TO OBTAIN RENEWAL WOULD CAUSE ALL OR PART OF OUR OPERATIONS TO BE SUSPENDED AND HAVE A MATERIAL ADVERSE EFFECT ON OUR FINANCIAL CONDITION

Our Company is subject to various PRC laws and regulations pertaining to the pharmaceutical industry. Our Company has attained certain certificates, permits, and licenses required for the operation of a pharmaceutical enterprise and the manufacturing of pharmaceutical products in the PRC. We obtained the Medicine Production Permit in December 2005, which is valid through December 31, 2010. We also obtained three GMP certificates which are effective through July 17, 2008, December 2, 2009, February 2, 2010 and April 17, 2011, respectively. The pharmaceutical production permits and GMP certificates are each valid for a term of five years and must be renewed before their expiration. During the renewal process, we will be re-evaluated by the appropriate governmental authorities and must comply with the prevailing standards and regulations, which may change from time to time. In the event that we are not able to renew the certificates, permits and licenses, all or part of our operations may be suspended by the government, which would have a material adverse affect on our financial condition. Furthermore, if escalating compliance costs associated with governmental standards and regulations restrict or prohibit any part of our operations, it may adversely affect our results of operations and profitability.

IF OUR PRODUCTS FAIL TO RECEIVE REGULATORY APPROVAL OR ARE SEVERELY LIMITED IN THE PRODUCTS SCOPE OF USE, THEN WE MAY BE UNABLE TO RECOUP CONSIDERABLE RESEARCH AND DEVELOPMENT EXPENDITURES ALREADY INCURRED

Our products that are approved to be manufactured as of December 31, 2006 include 17 medicines. There are 20 products in the stage of research and development as of December 31, 2006. The production of our pharmaceutical products is subject to the regulatory approval of the SFDA. The regulatory approval procedure for pharmaceuticals can be quite lengthy, costly, and uncertain. Depending upon the discretion of the SFDA, the approval process may be significantly delayed by additional clinical testing and require the expenditure of resources not currently available; in such an event, it may be necessary for us to abandon our application. Even where approval of the product is granted, it may contain significant limitations in the form of narrow indications, warnings, precautions, or contra-indications with respect to conditions of use. If approval of our product is denied, abandoned, or severely limited in terms of the scope of products use, it may result in the inability to recoup considerable research and development expenditures already incurred.

OUR RESEARCH AND DEVELOPMENT MAY BE COSTLY AND/OR UNTIMELY, AND THERE ARE NO ASSURANCES THAT OUR RESEARCH AND DEVELOPMENT WILL EITHER BE SUCCESSFUL OR COMPLETED WITHIN THE ANTICIPATED TIMEFRAME, IF EVER AT ALL

The research and development of our new and existing products and their subsequent commercialization plays an important role in our success. As of December 31, 2006, there are 20 products under research and development, including Hupan Keli, Troxerutin and Cerebroprotein Hydrolysate for

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Injection, Yimaikang Capsule, Bumetnide for Injection, Tiopronin, Omeprazole for Injection, Ceftriaxone Sodium and Tazobactam Sodium, Donepezil Dispersible Tablets, Mycophenolate Mofetil Granules, Cattle Encephalon Glycoside and Ignotin, Clindamycin Phosphate for Injection, Thymopetidium for Injection, Compand Diclofenac Sodium Injection, ShengQing Pian, rhCNTF, Pioglitazone HCL + metformin HCL, ACTOplus, Xinlin Tablets, Xinlin Oral Solution, rh_aFGF and Cefprozil Tablets. The research and development of new products is costly and time consuming, and there are no assurances that our research and development of new products will either be successful or completed within the anticipated time frame, if ever at all. There are also no assurances that if the product is developed, that it will lead to successful commercialization.

WE CANNOT GUARANTEE THE PROTECTION OF OUR INTELLECTUAL PROPERTY RIGHTS, AND IF INFRINGEMENT OR COUNTERFEITING OF OUR INTELLECTUAL PROPERTY RIGHTS OCCURS, THEN OUR REPUTATION AND BUSINESS MAY BE ADVERSELY AFFECTED

To protect the brand names of our products, we have registered and applied for registration of our trademarks in the PRC, where we have a major business presence.

All of our products are sold under these trademarks. As of the date of this Prospectus, we have not experienced any infringements of such trademarks for sales of pharmaceutical products, and as of the date of this Prospectus, we were not aware of any infringement of our intellectual property rights. However, there is no assurance that there will not be any infringement of our brand name or other registered trademarks or counterfeiting of our products in the future. Should any such infringement or counterfeiting occur, our reputation and business may be adversely affected. We may also incur significant expenses and substantial amounts of time and effort to enforce our intellectual property rights in the future. Such diversion of our resources may adversely affect our existing business and future expansion plans.

OUR REPUTATION AND BUSINESS MAY BE ADVERSELY AFFECTED AS A RESULT OF PRODUCT LIABILITY OR DEFECTIVE PRODUCTS

We may produce products which inadvertently have an adverse pharmaceutical effect on the health of individuals despite proper testing. Existing PRC laws and regulations do not require us to maintain third party liability insurance to cover product liability claims. However, if a product liability claim is brought against us, it may, regardless of merit or eventual outcome, result in damage to our reputation, breach of contract with our customers, decreased demand for our products, costly litigation, product recalls, loss of revenue, and the inability to commercialize some products. We currently are not aware of any existing or anticipated product liability claims with respect to our products.

WE RELY ON THE COOPERATION WITH CERTAIN RESEARCH LABORATORIES, PHARMACEUTICAL INSTITUTIONS, AND UNIVERSITIES, AND IF THESE INSTITUTIONS CEASE TO COOPERATE

WITH US AND WE CANNOT FIND OTHER SUITABLE SUBSTITUTE RESEARCH AND DEVELOPMENT PARTNERS, THEN OUR ABILITY TO DEVELOP NEW PRODUCTS MAY BE HINDERED AND OUR BUSINESS MAY BE ADVERSELY AFFECTED

Helpson cooperates with several research institutions including the Chinese Academy of Medical Sciences, China University of Pharmaceuticals, the Academy of Military Medical Science, the Chongqing Medical Industry Institute and China Sichuan University. Helpson relies to a certain extent on these institutions for its development of new products. There is no assurance that these institutions

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

will continue cooperating with Helpson to develop new products. In the event that these institutions cease to cooperate with Helpson and Helpson cannot find other suitable substitute research and development partners, our ability to develop new products may be hindered and our business may be adversely affected.

RISKS RELATED TO DOING BUSINESS IN CHINA

Helpson operates from facilities that are located in China. Accordingly, its operations must conform to governmental regulations and rules of the PRC.

THE PRC LEGAL SYSTEM HAS INHERENT UNCERTAINTIES THAT COULD LIMIT THE LEGAL PROTECTIONS AVAILABLE TO US

The PRC legal system is a civil law system based on written statutes. Unlike common law systems, it is a system in which decided legal cases have little precedential value. In the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing commercial matters. The overall effect of legislation enacted over the past 20 years has significantly enhanced the protections afforded to foreign-invested enterprises in China. However, these laws, regulations, and legal requirements are relatively recent and are evolving rapidly, and their interpretation and enforcement involve uncertainties. These uncertainties could limit the legal protections available to foreign investors.

The practical effect of the PRC's legal system on our business operations in China can be viewed from two separate but intertwined considerations. First, as a matter of substantive law, the Foreign Invested Enterprise laws provide significant protection from government interference. In addition, these laws guarantee the full benefit of corporate articles and contracts to Foreign Invested Enterprise participants. These laws, however, do impose standards concerning corporate formation and governance, which are not qualitatively different from the corporation laws found in the United States. Similarly, PRC accounting laws mandate accounting practices which may not be consistent with the U.S. Generally Accepted Accounting Principles. China accounting laws require that an annual "statutory audit" be performed in accordance with PRC accounting standards and that the books of account of a Foreign Invested Enterprise be maintained in accordance with PRC accounting laws. Article 14 of the PRC Wholly Foreign-Owned Enterprise Law requires a Wholly Foreign-Owned Enterprise to submit certain periodic fiscal reports and statements to designated financial and tax authorities, at the risk of business license revocation.

19

Second, while the enforcement of substantive rights may appear less clear than United States procedures, Foreign Invested Enterprises and Wholly Foreign-Owned Enterprises are PRC registered companies which enjoy the same status as other PRC registered companies in business-to-business dispute resolutions. The PRC legal infrastructure, however, is significantly different in operation from its United States counterpart, and may present a significant impediment to the operation of a Foreign Invested Enterprise.

PRC ECONOMIC REFORM POLICIES OR NATIONALIZATION COULD RESULT IN A TOTAL INVESTMENT LOSS IN OUR COMMON STOCK

Since 1979, the PRC government has reformed its economic policies. Because many reforms are unprecedented or experimental, they are expected to be refined and improved. Other political, economic and social factors, such as political changes, changes in the rates of economic growth, unemployment or inflation, or in the disparities in per capita wealth between regions within China, could lead

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

to further readjustment of the reform measures. This refining and readjustment process may negatively affect our operations.

Although the PRC government owns the majority of productive assets in China, in the past several years the government has implemented economic reform measures that emphasize decentralization and encourage private economic activity. Because these economic reform measures may be inconsistent or ineffectual, there are no assurances that:

- We will be able to capitalize on economic reforms;
- The Chinese government will continue its pursuit of economic reform policies;
- The economic policies, even if pursued, will be successful;
- Economic policies will not be significantly altered from time to time; or
- Business operations in China will not become subject to the risk of nationalization.

Over the last few years, China's economy has registered high growth rates. Recently, there have been indications that rates of inflation have increased. In response, the Chinese government recently has taken measures to curb this excessively expansive economy. These measures have included restrictions on the availability of domestic credit, reducing the purchasing capability of some of its customers, and limited recentralization of the approval process for purchases of certain foreign products. These austere measures alone may not succeed in slowing down the economy's excessive expansion or control inflation, and may result in severe dislocations in the Chinese economy. The PRC government may adopt additional measures to further combat inflation, including the establishment of freezes or restraints on certain projects or markets. These measures may adversely affect our operations.

There can be no assurance that the reforms to China's economic system will continue or that we will not be adversely affected by changes in China's political, economic, and social conditions and by changes in policies of the PRC government, such as changes in laws and regulations, measures which may be introduced to control inflation, changes in the rate or method of taxation, imposition of additional restrictions on currency conversion and remittance abroad, and reduction in tariff protection and other import restrictions.

20

YOU MAY EXPERIENCE DIFFICULTIES IN EFFECTING SERVICE OF LEGAL PROCESS, ENFORCING FOREIGN JUDGMENTS OR BRINGING ORIGINAL ACTIONS IN THE PRC BASED ON U.S. OR OTHER FOREIGN LAWS AGAINST THE COMPANY OR OUR MANAGEMENT

Helpson, our operating company, is incorporated under the laws of the PRC, and substantially all of our assets are located in the PRC. In addition, many of our directors, managers, and executive officers reside within the PRC, and substantially all of the assets of these persons are located within the PRC. As a result, it may not be possible to effect service of process within the United States or elsewhere outside the PRC upon certain of our directors, supervisors or executive officers, including with respect to matters arising under U.S. federal securities laws or applicable state securities laws. Moreover, the PRC does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the United States, the United Kingdom, Japan or many other countries. As a result, recognition and enforcement in the PRC of judgments of a court in the United States and any of the other jurisdictions mentioned above in relation to any matter may be difficult or impossible. Furthermore, an original action may be brought in the PRC against us, our

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

directors, managers, or executive officers only if the actions are not required to be arbitrated by PRC law and Helpson's articles of association, and only if the facts alleged in the complaint give rise to a cause of action under PRC law. In connection with any such original action, a PRC court may impose civil liability, including monetary damages.

BECAUSE WE RECEIVE SUBSTANTIALLY ALL OF OUR REVENUE IN RENMINBI, WHICH CURRENTLY IS NOT A FREELY CONVERTIBLE CURRENCY, AND THE PRC GOVERNMENT CONTROLS THE CURRENCY CONVERSION AND THE FLUCTUATION OF THE RENMINBI, WE ARE SUBJECT TO CHANGES IN THE PRCS' POLITICAL AND ECONOMIC DECISIONS

We receive substantially all of our revenues in Renminbi, which currently is not a freely convertible currency. The PRC government may, at its discretion, restrict access in the future to foreign currencies for current account transactions.

The value of the Renminbi against the U.S. dollar and other currencies fluctuates and is affected by, among other things, changes in the PRC's political and economic conditions. Since 1994, the conversion of Renminbi into foreign currencies, including Hong Kong and U.S. dollars, has been based on rates set by the People's Bank of China, which are set daily based on the previous day's inter-bank foreign exchange market rates and current exchange rates on the world financial markets. Since 1994, the official exchange rate for the conversion of Renminbi to U.S. Dollars generally has been stable. Any devaluation of the Renminbi, however, may materially and adversely affect the value of, and any dividends payable on, our shares in foreign currency terms, since we will receive substantially all of our revenues, and express our profits, in Renminbi. Our financial condition and results of operations also may be affected by changes in the value of certain currencies other than the Renminbi. Our results of operation may be adversely affected by changes in the political and social conditions in the PRC, and changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

21

The official exchange rate of the Renminbi to the U.S. Dollar had remained nearly fixed until July 21, 2005. On this date, the PRC government changed its policy of tying the value of the RMB to the U.S. dollar. Under the new policy, the Renminbi is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For nearly one and a half years since the implementation of this revaluation policy, there has been an approximately 5.79% appreciation of the Renminbi against the U.S. dollar. While the international reaction to the Renminbi revaluation generally has been positive, there remains significant international pressure on the PRC government to adopt an even more flexible currency policy, which could result in a further and more significant appreciation of the Renminbi against the U.S. dollar due to certain factors including a U.S. current (trade) account deficit with China. This floating exchange rate, and any further appreciation of the Renminbi that may result from such rate, could have various effects on the Company's financial statements. It is not possible to predict if the net effects of the further appreciation of the Renminbi, if it occurred, would be positive or negative for the Company.

THE GROWTH OF THE CHINESE ECONOMY HAS BEEN UNEVEN ACROSS GEOGRAPHIC REGIONS AND ECONOMIC SECTORS, AND A DOWNTURN IN CERTAIN REGIONS IN WHICH WE DO BUSINESS OR IN OUR ECONOMIC SECTOR WOULD SLOW DOWN OUR GROWTH AND PROFITABILITY

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

The growth of the Chinese economy has been uneven across geographic regions and economic sectors. For example, during the years between 1978 and 2000, the per capital GDP growth rate of Fujian Province in Southeastern China was 12% while that of Gansu Province in Northwestern China was 5.3% (Source: New China Statistical Materials Compilation for 50 Years and 2001 China Annual Statistics). There can be no assurance that growth of the Chinese economy will be steady or that any downturn will not have a negative effect on our business.

Our profitability may decrease due to a downturn in the Chinese economy. More specifically, the expansion of our sales area in the less economically developed central and western provinces of China will depend on those provinces achieving certain income levels.

ANY OCCURRENCE OF SERIOUS INFECTIOUS DISEASES, SUCH AS RECURRENCE OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CAUSING WIDESPREAD PUBLIC HEALTH PROBLEMS, COULD ADVERSELY AFFECT OUR BUSINESS AND RESULTS OF OPERATIONS

A renewed outbreak of SARS or other widespread public health problems in China, where all of our revenue is derived, and in Hainan, where our operations are headquartered, could have a negative effect on our operations. Our operations may be impacted by a number of public health-related factors, including the following:

- o quarantines or closures of our factories or subsidiaries which would severely disrupt its operations;
- o the sickness or death of key officers and employees; and
- o general slowdown in the Chinese economy.

22

Any of the foregoing events or other unforeseen consequences of public health problems could adversely affect our business and results of operations.

WE ARE SUBJECT TO THE ENVIRONMENTAL PROTECTION LAWS OF THE PRC

Our manufacturing process may produce by-products such as effluent, gases and noise, which are harmful to the environment. We are subject to multiple laws governing environmental protection, such as "The Law on Environmental Protection in the PRC" and "The Law on Prevention of Effluent Pollution in the PRC," as well as standards set by the relevant governmental bodies determining the classification of different wastes and proper disposal. We have properly attained a waste disposal permit for our manufacturing facility, which details the types and concentration of effluents and gases allowed for disposal. The temporary waste disposal permit will expire on September 28, 2009. We are responsible for the renewal of the waste disposal permit. There is no assurance that we will obtain the renewal of the waste disposal permit when the current permit expires.

China is experiencing substantial problems with environmental pollution. Accordingly, it is likely that the national, provincial and local governmental agencies will adopt stricter pollution controls. There can be no assurance that future changes in environmental laws and regulations will not impose costly compliance requirements on us or otherwise subject us to future liabilities. Our business's profitability may be adversely affected if additional or modified environmental control regulations are imposed upon us.

RECENT PRC REGULATIONS RELATING TO ACQUISITIONS OF PRC COMPANIES BY FOREIGN ENTITIES MAY LIMIT OUR ABILITY TO ACQUIRE PRC COMPANIES AND ADVERSELY AFFECT THE

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

IMPLEMENTATION OF OUR STRATEGY AS WELL AS OUR BUSINESS AND PROSPECTS

The PRC State Administration of Foreign Exchange, or SAFE, issued a public notice in January 2005 concerning foreign exchange regulations on mergers and acquisitions in China ("January Notice"). The January Notice states that if an offshore company controlled by PRC residents intends to acquire a PRC company, such acquisition will be subject to strict examination by the relevant foreign exchange authorities. The public notice also states that the approval of the relevant foreign exchange authorities is required for any sale or transfer by the PRC residents of a PRC company's assets or equity interests to foreign entities, such as us, for equity interests or assets of the foreign entities.

In April 2005, SAFE issued another public notice (the "April Notice") further explaining the January Notice. In accordance with the April Notice, if an acquisition of a PRC company by an offshore company controlled by PRC residents has been confirmed by a Foreign Investment Enterprise Certificate prior to the promulgation of the January Notice, the PRC residents must each submit a registration form to the local SAFE branch with respect to their respective ownership interests in the offshore company, and must also file an amendment to such registration if the offshore company experiences material events, such as changes in the share capital, share transfer, mergers and acquisitions, spin-off

23

transactions or use of assets in China to guarantee offshore obligations. The April Notice also provides that failure to comply with the registration procedures set forth therein may result in a restriction on the PRC company's ability to distribute profits to its offshore parent company. Pending the promulgation of detailed implementation rules, the relevant government authorities are reluctant to commence processing any registration or application for approval required under the SAFE notices.

In October 2005, SAFE promulgated another notice ("Decree No. 75") which repealed the above January Notice and April Notice. Decree No. 75 requires PRC residents and PRC corporate entities to register with and obtain approvals from relevant PRC governmental authorities in connection with their direct or indirect offshore investment activities.

Decree No. 75 requires registration by March 31, 2006 of direct or indirect investments previously made by PRC residents in offshore companies prior to the implementation of Decree No. 75 on November 1, 2005. If a PRC shareholder with a direct or indirect stake in an offshore parent company fails to make the required SAFE registration, the PRC subsidiaries of such offshore parent company may be prohibited from making distributions of profit to the offshore parent and from paying the offshore parent proceeds from any reduction in capital, share transfer or liquidation in respect of the PRC subsidiaries. Furthermore, failure to comply with the various SAFE registration requirements described above could result in liability under PRC law for foreign exchange evasion.

As it is uncertain how Decree No. 75 will be interpreted or implemented, we cannot predict how it will affect our business operations or future strategy. For example, we may be subject to more stringent review and approval process with respect to our foreign exchange activities, such as remittance of dividends and foreign-currency-denominated borrowings, which may adversely affect our results of operation and financial condition. In addition, if we decide to acquire a PRC company through the issuance of our capital stock, we cannot assure that the owners of the target company will be able to complete the necessary approval, filings and registrations for the acquisition. This may restrict our ability to implement our acquisition strategy and adversely affect

our business and prospects.

On August 8, 2006, six PRC regulatory agencies, including the Chinese Securities Regulatory Commission, or CSRC, promulgated a regulation (the "M&A Regulation") that became effective on September 8, 2006. This regulation, among other things, has some provisions that purport to require that an offshore special purpose vehicle, or SPV, formed for listing purposes and controlled directly or indirectly by PRC companies or individuals shall obtain the approval of the CSRC prior to the listing and trading of such SPV's securities on an overseas stock exchange.

Because the M&A Regulation became effective very recently, it remains uncertain how the M&A Regulation will be interpreted and enforced by the Chinese governmental authority such as the CSRC and the Ministry of Commerce. We cannot predict how the M&A Regulation will affect our business operations or future strategy. If the CSRC requires that we obtain its approval, we may be unable to obtain a waiver of the CSRC approval requirements, if and when procedures are established to obtain such a waiver. Any uncertainties and/or negative publicity regarding this CSRC approval requirement could have a material adverse effect on the trading price of our common stocks.

24

OUR BUSINESS MAY BE ADVERSELY AFFECTED AS A RESULT OF CHINA'S ENTRY INTO THE WORLD TRADE ORGANIZATION ("WTO") BECAUSE THE PREFERENTIAL TAX TREATMENTS AVAILABLE TO US MAY BE DISCONTINUED AND FOREIGN PHARMACEUTICAL MANUFACTURERS MAY COMPETE WITH US IN THE PRC PHARMACEUTICAL INDUSTRY

The PRC became a member of the WTO on December 11, 2001. The current tax benefits enjoyed by our Company may be regarded as unfair treatment by other members of the WTO. Accordingly, the preferential tax treatments available to us may be discontinued. In such circumstances, our profitability may be adversely affected. In addition, we may face additional competition from foreign pharmaceutical manufacturers if they set up their production facilities in the PRC or form Sino-foreign joint ventures with our competitors in the PRC. In the event that we fail to maintain our competitiveness against these competitors, our profitability may be adversely affected.

RISKS RELATED TO OUR COMMON STOCK

THE MARKET PRICE FOR OUR COMMON STOCK MAY BE VOLATILE WHICH COULD RESULT IN A COMPLETE LOSS OF YOUR INVESTMENT

The market price for our common stock is likely to be highly volatile and subject to wide fluctuations in response to factors including the following:

- o actual or anticipated fluctuations in our quarterly operating results,
- o announcements of new products by us or our competitors,
- o changes in financial estimates by securities analysts,
- o conditions in the pharmaceutical market,
- o changes in the economic performance or market valuations of other companies involved in pharmaceutical production,
- o announcements by our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments,
- o additions or departures of key personnel, or
- o potential litigation,

In addition, the securities markets have from time to time experienced

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

significant price and volume fluctuations that are not related to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.

25

WE MAY ISSUE ADDITIONAL SHARES OF OUR CAPITAL STOCK TO RAISE ADDITIONAL CASH FOR WORKING CAPITAL; IF WE ISSUE ADDITIONAL SHARES OF OUR CAPITAL STOCK, OUR STOCKHOLDERS WILL EXPERIENCE DILUTION IN THEIR RESPECTIVE PERCENTAGE OWNERSHIP IN US THE COMPANY

We may issue additional shares of our capital stock to raise additional cash for working capital. Although the Warrants issued in this Offering will have anti-dilution protection, there are no anti-dilution protection or preemptive rights in connection with our common stock. Thus, the percentage ownership of existing holders of common stock, including the Shares issued in this Offering, may be diluted in their respective percentage ownership in us if we issue additional shares of our capital stock.

A LARGE PORTION OF OUR COMMON STOCK IS CONTROLLED BY A SMALL NUMBER OF STOCKHOLDERS AND AS A RESULT, THESE STOCKHOLDERS ARE ABLE TO INFLUENCE AND ULTIMATELY CONTROL THE OUTCOME OF STOCKHOLDER VOTES ON VARIOUS MATTERS

A large portion of our common stock is held by a small number of stockholders. For instance, Heung Mei Tsui holds 41.04% and Zhilin Li holds 26.86% of the Company's common stock, respectively, as of the date of this Prospectus. As a result, these two stockholders are able to influence and ultimately control the outcome of stockholder votes on various matters, including the election of directors and other corporate transactions including business combinations. In addition, the occurrence of sales of a large number of shares of our common stock, or the perception that these sales could occur, may affect our stock price and could impair our ability to obtain capital through an offering of equity securities. Furthermore, the current ratios of ownership of our common stock reduce the public float and liquidity of our common stock which can in turn affect the market price of our common stock.

THERE IS CURRENTLY A LIMITED TRADING MARKET FOR OUR COMMON STOCK WHICH MAY MAKE IT DIFFICULT TO SELL SHARES OF OUR COMMON STOCK

Our common stock is currently traded in the over-the-counter market through the Over-the-Counter Bulletin Board (OTC Bulletin Board). The quotation of our shares on the OTC Bulletin Board may result in a less liquid market available for our existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future. While there is an active trading market for our common stock, it is small. Further, there can be no assurance that an active trading market will be maintained. We cannot assure you that our common stock will ever be included for trading on any stock exchange or through any other quotation system (including, without limitation, the NASDAQ Stock Market).

WE ARE LIKELY TO REMAIN SUBJECT TO "PENNY STOCK" REGULATIONS AND AS A CONSEQUENCE THERE ARE ADDITIONAL SALES PRACTICE REQUIREMENTS AND ADDITIONAL WARNINGS ISSUED BY THE SEC

26

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

As long as the trading price of our common stock is below \$5.00 per share, the open-market trading of our common stock will be subject to the "penny stock" rules of the SEC. The "penny stock" rules impose additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors (generally those with assets in excess of \$1,000,000 or annual income exceeding \$200,000 or \$300,000 together with their spouse). For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of securities and have received the purchaser's written consent to the transaction before the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the broker-dealer must deliver, before the transaction, a disclosure schedule prescribed by the SEC relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited market in penny stocks. These additional burdens imposed on broker-dealers may restrict the ability of broker-dealers to sell the common stock and may affect a stockholder's ability to resell the common stock.

There can be no assurance that our common stock will qualify for exemption from the "penny stock" rules. In any event, even if our common stock is exempt from such rules from such rules, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of a "penny stock" if the SEC finds that such a restriction would be in the public interest.

Stockholders should be aware that, according to SEC Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (iii) boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (iv) excessive and undisclosed bid-ask differential and markups by selling broker-dealers; and (v) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices and with consequent investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market.

WE ARE RESPONSIBLE FOR THE INDEMNIFICATION OF OUR OFFICERS AND DIRECTORS UNDER CERTAIN CIRCUMSTANCES WHICH COULD RESULT IN SUBSTANTIAL EXPENDITURES, WHICH WE MAY BE UNABLE TO RECOUP

Our bylaws provide for the indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney's fees and other expenses incurred by them in any litigation to which they become a party arising from their association with or activities on behalf of us. This indemnification policy could result in substantial expenditures, which we may be unable to recoup.

COMPLIANCE WITH THE SARBANES-OXLEY ACT COULD COST HUNDREDS OF THOUSANDS OF

DOLLARS, REQUIRE ADDITIONAL PERSONNEL AND REQUIRE HUNDREDS OF MAN HOURS OF EFFORT, AND THERE CAN BE NO ASSURANCE THAT WE WILL HAVE THE PERSONNEL, FINANCIAL RESOURCES OR EXPERTISE TO COMPLY WITH THESE REGULATIONS

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

The Public Company Accounting Reform and Investor Protection Act of 2002, better known as Sarbanes-Oxley, is the most sweeping legislation to affect U.S. publicly traded companies in the last 70 years. Sarbanes-Oxley created a set of complex and burdensome regulations upon publicly traded companies. Compliance with such regulations requires hundreds of thousands of dollars, additional personnel and hundreds of man hours of effort. There can be no assurance that we will have the personnel, financial resources or expertise to comply with these regulations.

Section 404 of the Sarbanes-Oxley Act of 2002 requires management to assess its internal controls over financial reporting and requires auditors to attest to that assessment. Current regulations of the SEC will require us to include this assessment and attestation in our Annual Report on Prospectus commencing with the annual report for our fiscal year ended December 31, 2007.

We will incur significant increased costs in implementing and responding to these requirements. In particular, the rules governing the standards that must be met for management to assess its internal controls over financial reporting under Section 404 are complex and require significant documentation, testing and, if necessary, possible remediation. Our process of reviewing, documenting and testing our internal controls over financial reporting may cause a significant strain on our management, information systems and resources. We may have to invest in additional accounting and software systems. We may be required to hire additional personnel and to use outside legal, accounting, and advisory services. In addition, we will incur additional fees from our auditors as they perform the additional services necessary for them to provide their attestation. If we are unable to favorably assess the effectiveness of our internal controls over financial reporting when we are required to, or if our independent auditors are unable to provide an unqualified attestation report on such assessment, then we may be required to change our internal controls over financial reporting to remediate deficiencies. In addition, investors may lose confidence in the reliability of our financial statements, causing our stock price to decline.

OUR HOLDING COMPANY STRUCTURE MAY LIMIT THE PAYMENT OF DIVIDENDS

We have no direct business operations, other than our ownership of our subsidiaries. While we have no current intention of paying dividends, should we decide in the future to do so, as a holding company, our ability to pay dividends and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries and other holdings and investments. In addition, our operating subsidiaries, from time to time, may be subject to restrictions on their ability to make distributions to us, including as a result of restrictive covenants in loan agreements, restrictions on the conversion of local currency into U.S. dollars or other hard currency and other regulatory restrictions as discussed below. PRC regulations currently permit the payment of dividends only out of accumulated profits as determined in accordance with PRC accounting standards and regulations. Our subsidiaries in China are

also required to set aside a portion of their after tax profits according to PRC accounting standards and regulations to fund certain reserve funds. Currently, our subsidiaries in China are the only sources of revenues or investment holdings for the payment of dividends. If they do not accumulate sufficient profits under PRC accounting standards and regulations to first fund certain reserve funds as required by PRC accounting standards, we will be unable to pay any dividends.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

FORWARD-LOOKING STATEMENTS

This Prospectus contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act (the "Exchange Act"). We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including, among other things:

- general economic and business conditions, both internationally and in the PRC markets,
- our expectations and estimates concerning future financial performance, financing plans, and the impact of competition,
- our ability to implement our growth strategy,
- anticipated trends in our business,
- advances in technologies, and
- other risk factors set forth under "Risk Factors" in this Prospectus.

In addition, in this Prospectus, we use words such as "anticipates," "believes," "plans," "expects," "future," "intends," and similar expressions to identify forward-looking statements.

We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Prospectus. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this Prospectus may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.

Notwithstanding the above, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act expressly state that the safe harbor for forward looking statements does not apply to companies that issue penny stock. Because we issue penny stock, the safe harbor for forward looking statements does not apply to us.

USE OF PROCEEDS

This Prospectus relates to shares of our common stock that may be offered and sold from time to time by the selling stockholders. We will not receive any proceeds from the sale of shares of common stock in this offering. However, we will receive the exercise price of any common stock we issue to the selling stockholders upon exercise of the warrants. We intend to use such proceeds received from the exercise of the warrants, if any, for working capital and

29

general corporate purposes.

MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Our common stock is traded on the OTCBB under the symbol "CPHI.OB". The following table sets forth the price representing the range of high and low closing sale prices for our common stock as reported during the fiscal years ended December 31, 2005 and 2006.

Quarter Ended	High	Low
-----	-----	-----

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

2006		
4th Quarter	\$2.35	\$1.30
3rd Quarter	\$1.60	\$1.07
2nd Quarter	\$1.70	\$1.15
1st Quarter	\$2.05	\$1.05
2005		
4th Quarter	\$2.65	\$1.70
3rd Quarter	\$2.25	\$1.05
2nd Quarter	\$2.00	\$0.40
1st Quarter	\$0.55	\$0.35

As of March 29, 2007, the closing price of our common stock on the OTCBB was \$1.93. As of March 29, 2007, the stockholders' list for our common stock showed 204 registered shareholders of record, which figure does not take into account those stockholders whose certificates are held in the name of broker-dealers or other nominees and 37,228,938 shares of common stock issued and outstanding.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF PLAN OF OPERATION

FORWARD-LOOKING STATEMENTS

The following discussion of China Pharma Holdings, Inc.'s ("China Pharma") financial condition and results of operations should be read in conjunction with its financial statements and the related notes, and the other financial information included elsewhere in this Prospectus.

This filing contains forward-looking statements. The words "anticipated," "believe," "expect", "plan," "intend," "seek," "estimate," "project," "could," "may," and similar expressions are intended to identify forward-looking statements. These statements include, among others, information regarding future operations, future capital expenditures, and future net cash flow. Such statements reflect China Pharma management's current views with respect to future events and financial performance and involve risks and uncertainties,

including, without limitation, general economic and business conditions, changes in foreign, political, social, and economic conditions, regulatory initiatives and compliance with governmental regulations, the ability to achieve further market penetration and additional customers, and various other matters, many of which are beyond China Pharma's control. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated or otherwise indicated. Consequently, all of the forward-looking statements made in this filing are qualified by these cautionary

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

statements and there can be no assurance of the actual results or developments.

I. The year 2006 in brief.

2006 saw another year of sound growth and outstanding financial performance at China Pharma. The Company's whole revenue increased by over 150% to a historical record high of \$21.84 million in US dollars. This fast growth has all been built on an organic basis since the inception of Company in January, 2005; particularly, in addition to some traditionally classical products, the growth of sales was primarily attributed to the development of new products for the fiscal year 2006. China Pharma maintained its orientation of launching new products in an increasingly competitive market and explored potential markets in a wide domestic base.

The financial performance in year 2006 improved significantly compared to years before. Gross profit grew dramatically by 125% to US \$10 million and the net income, without consideration of foreign currency translation adjustment, has been doubled to US \$8.59 million. Major outlays have been placed on the development of new product pipelines and the construction of new marketing activities.

Considering the newly fulfilled fund-raising activities, there was a slight decrease in the basic and diluted earnings per common shares to US\$0.25, however, weighted-average common shares outstanding has grown three times to 34.72 million, in an anticipation of sustainable profit generation.

China Pharma has built up intense cooperation among biological, chemical and medical institutions to deliver more functional products tailored to the demand of particular populations of the end-user. According to management's goals, our company is dedicated to achieve stable profits growth. We operate the business by relevant strategic principles, which have been proven successful. Thoroughly, exploring the potential in the pharmaceutical field is the key to our success. Further, we also are concerned with corporate governance as a modern enterprise. In the near future, we will establish a more systematic and long lasting process of internal controls for prospective development and to the benefit of our shareholders.

II. Business Overview

China Pharma is primarily engaged in the research, development, manufacture, and marketing of pharmaceutical and nutritional supplements. Especially, we have launched an anti-flu product named PuSenOK in 2005, which is the only anti flu medicine in the market mixed with pseudo ephedrine hydrochloride, a non-drowsy formula with a runny nose suppressant. We plan to expand our biotechnology

31

product series. Based on the foundation established by some of Helpson's widely recognized medicine labels such as Neurotrophicpeptide, we have been and will continue to launch a variety of biological medicines, including the brain peptide injection, injected hepatocyte growth-promoting factors, as well as new genetic medicines, rh-CNTF and rh-AFGF, which are expected to fuel us a new growth following that of Neurotrophicpeptide.

The product of Buflomedil Hydrochloride (including raw material, injection and troche) has been:

- o Designated as the key technology project in Hainan in 2003 by Hai'kou Municipality.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

- o Received the best technology commercialization award in Hainan in 2004 by Hainan Scientific and Technological Result Examination Committee.
- o Awarded the national key new products certificate in 2003 by the State Science and Technology Department, State Taxation Bureau, Ministry of Commerce, State Bureau of Quality Supervision, Inspection and Quarantine, and State Environmental Protection Bureau.

Since the year 2003 Helpson attained GMP authentication and the prize as the "best enterprise for supporting SARS medicine" awarded by Hainan Food and Drug Administration, demonstrating our leading position in the market. In the year of 2006, our products have been distributed to more than 29 provinces, sovereignties, and autonomous regions around China. Our sales network covers approximately 16 sales offices and approximately 550 proxy agents. The main channels we use to deliver our products include: (1) Distribution system (Proxy Agency); (2) Direct sale system to hospitals; (3) Direct representation in clinic hospitals through medical representatives; and (4) Distribution of products to local medical companies through logistics companies.

Retrospectively, on June 16, 2005, Onny Investment Limited ("Onny") acquired all the outstanding shares in Hainan Helpson Medicine and Bio-Technology Co. Ltd. ("Helpson"), a private Chinese company, in exchange for the assumption of obligations to make cash payments to the Helpson's shareholders in a form of common stock dividend from Helpson of \$4,154,041, the assumption of \$4,646,409 of other liabilities and the issuance of non-interest bearing promissory notes totaling \$3,413,265 payable three months after Helpson obtained a business license in the PRC as a wholly foreign owned entity. The acquisition of Helpson was recognized as a business combination.

Then after, on October 19, 2005, Onny issued 10,000 preferred shares in exchange for \$4,313,000 in cash, net of offering costs and estimated registration costs, and on that same date, those preferred shares were converted into 10,000 Onny common shares. Also on October 19, 2005, Onny was reorganized as a wholly-owned subsidiary of the Company. The reorganization was accomplished by the original Onny common shareholder exchanging her 29,700 Onny common shares for 20,555,329 common shares of China Pharma and for the commitment by China Pharma to issue the original Onny common shareholder 4,723,056 common shares following an amendment of the China Pharma articles of incorporation increasing the number of common shares authorized to 60,000,000 shares from 30,000,000 shares. In addition, the prior Onny preferred shareholders exchanged their 10,000 Onny common shares for 6,944,611 common shares of China Pharma.

32

Additionally, on February 1, 2007, China Pharma fulfilled an offering of Units priced at \$1.70 per Unit consisting of one share of Company common stock and a warrant to purchase one-half of a share of Company common stock at an exercise price of \$2.38 per share. China Pharma received gross proceeds in the aggregate amount of \$4,259,900; and the net proceeds, after deducting the related offering expenses of \$445,258, amounted to \$3,814,741. In total, it issued an aggregate of 2,505,882 shares of common stock and issued three-year warrants to purchase an aggregate of 1,252,941 shares of Company's common stock to 17 accredited investors.

III. Trend in the Market.

Studies show that, with the world's expanding population, not only larger but older, ever growing numbers of people have diseases aging, such as cancer,

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Alzheimer's disease, diabetes and rheumatoid arthritis which have already become prevalent, especially in developed areas. In a growing and aging population, people need to find more effective methods of treatment.

In addition, patient empowerment has been another factor in high-quality healthcare. Many are better informed about the importance of health issues and medical advancement. Naturally, people today are demanding greater care and access to the latest medical procedures and medicines.

Helpson regards this market trend as an opportunity. However, the best way to develop it is to find our business risks beforehand, with a hope of alleviating or eliminating these potential side-effects. Generally speaking, there are three aspects of risks.

o External Risk

In recent years, Chinese medical system reform has been occurring, resulting in the State Department establishment of a basic medical insurance system for the workers in cities and towns. Considering the social environment and the governmental policy in pharmaceutical industry in PRC, a high speed growth of sales can be expected due to a kind of regional protectionism in the industry. Competition will also be intensive across the industry overall. Currently, company's existing products are competitive in the market and possess potential growth power in its existing products and topic selection, however, from a long-term perspective, some major western medicine producers are also seeking Chinese market share. This will make the company face intensive competition in this natural herb product market.

o Operation Risk

One of the major uncertainties in the Company is the purchase of raw materials. Raw material is primarily affected by the geographical environment in Hainan Province. As it is a long way for transportation, in order for the need of production, the Company has to store large amounts of inventory according inventory budget. In addition, partial raw material need to be specifically ordered, with higher storage needs. Meanwhile, since the increasing volume in sales, the Company needs to store large volume of packaging material, to meet the needs of production and sales.

33

o Foreign Currency Risk

Substantially all of our operations are conducted in the PRC. Our sales and purchases are conducted within the PRC in Chinese Renminbi. As a result, the effect of exchange rate fluctuation would inevitably to be considered to be material to our business operations.

All of our revenues and expenses are denominated in Renminbi. But we use the United States dollar for financial reporting purposes. Conversion of Renminbi into foreign currencies is regulated by the People's Bank of China through a unified floating exchange rate system. Although the PRC government has stated its intention to support the value of the Renminbi, there could be no assurance that such exchange rate will not again become volatile or that the Renminbi will not devalue significantly against the U.S. dollar. Exchange rate fluctuations may adversely affect the value, in U.S.dollar terms, of our net assets and income derived from its operations in the PRC.

IV. Critical Accounting Policies and Estimates

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

The overall discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. We believe the following are the critical accounting policies that impact the financial statements, some of which are based on management's best estimates available at the time of preparation. Actual experience may differ from these estimates.

Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Accounts Receivable - During the normal course of business, we keep unsecured credit to our customers and review our accounts receivable on a regular basis to determine if the bad debt allowance is adequate at the end of the period. We record an allowance for bad debts based on age of outstanding accounts receivables at the end of the period in accordance with generally accepted accounting principles in the PRC. The percentage of a trade receivable that is deemed doubtful is as follows: 100% after 720 days; 50 % after 360 days; and 7.5% up to 360 days.

Intangibles- Under the Statement of Accounting Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets," all goodwill and certain intangible assets determined to have indefinite lives are not amortized, but are tested for impairment at least annually. Other intangible assets are amortized over their useful lives and reviewed for impairment in accordance with SFAS No. 144 "Accounting for Impairment or Disposal of Long-Lived Assets."

Revenue Recognition- We recognize revenue when all four of the following criteria are met : (i) persuasive evidence has been received that there is an enforceable agreement; (ii) the products have been delivered or the services have been performed; (iii) the selling price is fixed or determinable; and (iv) collectibility is reasonably assured.

34

Concentrations and Credit Risks - As all of the Company's operations are conducted in the PRC, and therefore our operations may be adversely affected by significant political, economic and social uncertainties in the PRC. Although the Chinese government has pursued economic reform policies in the past, we cannot assure you that the Chinese government will continue to pursue such policies or that such policies will not be significantly altered, especially in the event of a change in leadership, social or political disruption or unforeseen circumstances affect China's political, economic and social conditions.

The Company's revenue are denominated in the PRC's currency of Renminbi ("CNY" or "(Y)"), which must be converted into other currencies before remittance out of the PRC. Both the conversion of CNY into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

We could give no assurance that the Chinese government's pursuit of economic reforms will be consistent or effective.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

In addition, as a common practice in the Industry, some customers may not repay their debts under the credit periods granted or may repay slowly as the volume of purchase increase. In this regard, there is no assurance that trade receivables could be repaid completely as due on a timely basis.

Research and Development Costs- Research and development costs are expensed as incurred. The costs of material and equipment acquired or constructed for research and development and having alternative future uses are classified as property and equipment and depreciated over their estimated useful lives.

Foreign Currency Translation- Our functional currency is the Chinese Yuan. Our financial statements are translated into United States dollars, using the exchange rates at the end of the period as to assets and liabilities and average exchange rates as to revenue and expenses. Capital accounts are translated at their historical exchange rates when the transaction occurred. Net gains and losses resulting from foreign exchange translations are included in the statements of operations and stockholders' equity as other comprehensive income.

The quotation of the exchange rates does not imply free convertibility. All foreign exchange transactions continue to take place either through the People's Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rate quoted by the People's Bank of China. Approval by the People's Bank of China or other institutions requires us to submit a payment application form together with invoices, shipping documents and signed contracts.

V. Analysis to the financial performance

The following chart sets forth our statements of operations for the twelve months ended December 31, 2006, and for the period from January 12, 2005 (date

35

of inception) through December 31, 2005. Both are denominated in U.S. dollars.

Figure 1:

CHINA PHARMA HOLDING, INC CONSOLIDATED STATEMENTS OF OPERATIONS		
	For the year ended December 31, 2006	For the Period from January 12, 2005 (Date of Inception) through December 31, 2005
	-----	-----
Revenue	\$ 21,843,262	\$ 8,657,813
Cost of Revenue	11,745,815	4,166,965
	-----	-----
Gross Profit	10,097,447	4,490,848
	-----	-----
Operating expenses:		
Selling expenses	260,128	106,129
General and administrative	1,213,828	140,903
	-----	-----

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Total Operating Expenses	1,473,956	247,032
Income from Operations	8,623,491	4,243,816
Non-operating income (expenses):		
Interest income	991	769
Interest expense	(145,881)	(186,452)
Other Income (Expense)	108,485	(6,482)
Total Non-operating Income (Expense)	(36,405)	(192,165)
Income Before Taxes	8,587,086	4,051,651
Income tax expense	-	252,101
Net Income	\$ 8,587,086	\$ 3,799,550
Comprehensive income-foreign currency translation adjustments	563,945	99,926
Comprehensive income	\$ 9,151,031	\$ 3,899,476
Basic and Diluted Earnings per Common Share	\$ 0.25	\$ 0.34
Weighted-average Common Shares Outstanding	34,723,056	11,289,480

36

Figure 2:

	CONSOLIDATED STATEMENTS OF OPERATIONS			
	For the year ended December 31, 2006	As a percentage of Revenue	For the Period from January 12, 2005 (Date of Inception) through December 31, 2005.	As a percentage of Revenue
Revenue	\$21,843,262			8,657,813
Cost of Revenue	11,745,815	54%	4,166,965	48%
Gross Profit	10,097,447	46%	4,490,848	52%
Operating expenses				
Selling expenses	260,128	1.2%	106,129	1.2%
General and administrative	1,213,828	5.6%	140,903	1.6%
Total Operating Expenses	1,473,956	7%	247,032	3%
Income from Operations	8,623,491	39%	4,243,816	49%
Non-operating income (expenses):				
Interest income	991	0.0%	769	0.0%

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Interest expense	(145,881)	(0.7%)	(186,452)	(2.2%)
Other Income (Expense)	108,485	0.5%	(6,482)	0.1%
Total Non-operating Income (Expense)	(36,405)	(0.2%)	(192,165)	(2.2%)
Income Before Taxes	8,587,086	39.3%	4,051,651	46.8%
Income tax expense	--		252,101	2.9%
Net Income	\$ 8,587,086	39.3%	3,799,550	43.9%
Comprehensive income-foreign currency translation adjustments	563,945	2.6%	99,926	1.2%
Comprehensive income	\$ 9,151,031	41.9%	3,899,476	45.0%

37

Revenue: Revenue for the twelve months ended December 31, 2006 was \$21,843,262, a dramatic increase of \$13,185,449, around 152.30%, from the revenue of \$8,657,813 for the period ended December 31, 2005. One of the major driving forces was derived from a launch of new products and enhancement of some existing products this year. For example, the products of AFGF, Roxithromycin dispersible tablets and Gastrodin Injection all had predominant performance to the overall sales. Meanwhile, a distribution network has spread over a majority of the provinces in China, about 29 provinces or regions. Further, with the improvement of production capacity, a significant improvement in sales has been made possible by an increased yield capacity, both in new and existing products.

Cost of Revenue: Compared to the corresponding figure last year, cost of sales has increased as well, about 181.90% from \$4,166,965 for the period as of December 31, 2005 to the amount of \$11,745,815 for the year as of December 31, 2006. As a percentage of revenues, the cost of sales increased from 48% for the period as of December 31, 2005 to that of 54% for the period as of December 31, 2006. The increased cost of sales was primarily as a result of the increased revenue during the fiscal year 2006.

Gross Margin: There was an increase in gross margin to \$10,097,447 for the period as of December 31, 2006 from that of \$4,490,848 for the period as of December 31, 2005. However, a percentage of revenue, gross margin percentage decreased from 52% in 2005 to 46% in 2006. The decreased gross margin was mainly due to an increase in cost of sales rather than the growth of overall operation revenue.

Selling Expenses: Selling expense has also increased at the same time, primarily for the purpose of distribution. Relative to the total operating expenses,

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

selling expenses approximately accounted for 18% for the year ended December 31, 2006. It was a dramatic decrease due to good management of distribution, compared to 43% of operating expenses for the year ended December 31, 2005 .

General & Administrative Expenses: There was an increase in general and administrative expense for the year ended December 31, 2006 to \$1,213,828 from a corresponding amount of \$140,903 for the year ended December 31 2005. There were two major reasons. Due to the specific nature of pharmaceutical industry in China, most of the sales will be realized through receivables. Accordingly, an increased bad debt provision has been accrued. However, another important reason was due to an increase in R&D, up 281.23%.

For the fiscal years ended December 31, 2006 and December 31, 2005, R&D expense has covered a variety of pharmaceutical products such as Cardiovascular and Cerebrovascular drugs, Natural Herb drugs, Diuretics drugs, Liver protecting drugs, inhibitor drugs and others. In the next 2-3 years, our company will

38

continue focusing on R&D, for sustainable development of product varieties. The outlay for R&D is expected to be around 5-10% as a percentage of total revenue for each respective year.

Thus, as a percentage of revenues, the total operating expenses has grown to 7% for the period as of December 31, 2006, from a 3% for that of fiscal year 2005.

Income from Operations: With the large increase in sales, although there was a relative decrease in income from operations against revenue, from 49% for the period as of December 31, 2005 to 39% for the period as of December 31, 2006, it can be seen an absolute increase from \$4,243,816 to the amount of \$8,623,491 for the corresponding fiscal years.

Financial Cost: Interest income and expense has stayed stable from last year, with a net interest expense \$144,890 ended December 31, 2006 from a net amount of \$185,683 for period as of December 31, 2005. In addition, government grants including 'Purchase of domestically made machinery refund' and other tax refunds have been credited for business support this year, which resulted in the increase in Other Income amounting to \$108,485 for the year ended December 31, 2006.

Income Tax: During the year, the Company qualified for a preferential income tax policy in China, i.e., "two-year free; third-fifth year half" for profit-realized in a foreign invested company (FIE). Therefore, there was no enterprise income tax this year as the company has been recognized as a FIE this year.

Net Income: Net income, without consideration of foreign currency translation factor, was \$8,587,086 for the year ended December 31, 2006. It was more than 126% higher than the net income for the period ended December 31, 2005 which was \$3,799,550. As a percentage of revenue, there was a decrease from 44% to 39% for the fiscal years respectively. Moreover, given the foreign currency translation influence, comprehensive income is \$9,151,031 for the year ended December 31, 2006, a 134.7% increase compared to \$3,899,476 for last year ended December 31, 2005. The comparative result of operations has shown an organic growth of business in sales, with a dramatic increase in sales and slight decrease in the cost of sales and related expenses as a percentage of sales in total.

VI. Analysis of the financial position: Liquidity and CapitalResource

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

As of December 31, 2006, cash and cash equivalents were \$656,441, which has increased by 42.3% compared to the ending balance as of December 31, 2005 at \$461,220. Meanwhile, during the year, the Company has borrowed short-term loans of \$6,533,649 as of December 31, 2006. It was primarily for working capital.

39

Figure 3:

 Summary of Cash Flow

\$,000	Years Ended 2006	December, 31 2005
	In thousands	
Net cash provided by (used in) operating activities	(1,736.33)	(449.10)
Net cash provided by (used in) investing activities	(192.00)	(341.52)
Net cash provided by (used in) financing activities	2,105.43	1,248.73
Effect of Foreign Exchange translation	18.13	3.11
Net cash Flow	195.22	461.22

Net cash used in operating activities was \$1,736,333 for the year ended at December 31, 2006, nearly three times more compared to \$ 449,095 for the period ended at December 31, 2005. One of the significant reasons for this large increase was due to the increase in trade account receivables and inventory. Confidence can be seen from the stable improvement of trade capability in the Company.

Net cash used in investing activities, for purchase of property, equipment and that of intangible assets have been lowered to \$182, 346 and \$9,657 respectively at the year end of December 31, 2006. There was not any cash generated from the purchased of entity in the year 2006, compared to that of \$131,336 in the year 2005.

Net cash proceed for financing activities has grown up to \$2, 105,430 as of December 31, 2006, 69% higher relative to the proceeds of \$1,248,727 for the period as of December 31, 2005. As analyzed above, the increase was primarily because of the proceeds from note payables and loans from shareholders. For the fiscal year as of December 31 2006, a \$2,140,943 bank loan was borrowed for working capital purpose.

Capital expenditures: For the past three fiscal years ended December 31, 2006, there have been capital expenditures of \$1,157,126, primarily for GMP Plant Construction, purchase of equipment and intangible assets. As of December 31, 2006, there was no material commitments for capital expenditures other than for those expenditures incurred in an ordinary course of business.

VII. Off-Balance

Sheet Arrangements There was no off-balance sheet arrangement in the Company.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

VIII. Commitments

In January 2006, the Company converted its dividend payable of \$4,304,371 into short-term note bearing interest at the rate of 2.25% per annum.

40

IX. New Accounting Pronouncements

In December 2004, FASB issued Statements of Financial Accounting Standards (SFAS) 123, "Share-Based Payment" (SFAS 123R). SFAS No. 123R revises FASB Statement No. 123, "Accounting for Stock-Based Compensation," and supersedes APB Opinion No. 25, "Accounting for Stock Issued to Employees." SFAS 123R focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions. SFAS 123R requires companies to recognize in the statement of operations the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value of such awards (with limited exceptions). SFAS 123R is effective as of the first reporting period beginning after December 15, 2005. The Company has not yet quantified the effects of the adoption of SFAS 123R, but it is expected that the new standard will result in significant stock-based compensation expense. The pro forma effects on net loss and loss per share if the Company had applied the fair value recognition provisions of the original SFAS 123R on stock compensation awards (rather than applying the intrinsic value measurement provisions of APB 25) are disclosed above in stock-based compensation. Although such pro forma effects of applying the original SFAS 123 may be indicative of the effects of adopting SFAS 123R, these provisions differ in some important respects.

In December 2004, the FASB issued SFAS Statement No. 153, "Exchanges of Non-monetary Assets—an amendment of APB Opinion No. 29" (SFAS 153). The Company adopted the provisions of SFAS 153 in January 2006. The adoption of SFAS 153 did not have a material impact on the Company's consolidated financial statements.

In May, 2005, the FASB issued SFAS No. 154, "Accounting Changes and Errors Corrections—an amendment to APB Opinion No. 20 and Statement of Financial Accounting Standards No. 3" (SFAS 154). The Company adopted the provisions of SFAS 154 in January 2006. The adoption of SFAS 154 did not have a material impact on the Company's consolidated financial statements.

In February 2006, the FASB issued SFAS No. 155, Accounting for Certain Hybrid Financial Instruments -- an amendment of FASB Statements No. 133 and 140 (SFAS 155). SFAS 155 eliminates the prohibition on a qualifying special-purpose entity from holding a derivative financial instrument that pertains to a beneficial interest other than another derivative financial instrument. SFAS 155 is effective for the Company for all financial instruments acquired or issued beginning January 1, 2007. The impact of SFAS No. 155 will depend on the nature and extent of any new derivative instruments entered into after the effective date.

In March 2006, the FASB issued SFAS No. 156, Accounting for Servicing of Financial Assets - an amendment of FASB Statement No. 140 (SFAS 156). SFAS 156 amends SFAS 140 requires an entity to recognize a servicing asset or servicing liability each time it undertakes an obligation to service a financial asset. It also requires all separately recognized servicing assets and servicing liabilities to be initially measured at fair value, if practicable. SFAS 156 permits an entity to use either the amortization method or the fair value measurement method for each class of separately recognized servicing assets and servicing liabilities. SFAS 156 is effective for the Company as of January 1,

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

2007. The impact of adoption of this statement on the Company's consolidated financial statements, if any, has not yet been determined.

In July 2006, the FASB issued Interpretation No. 48, "Accounting for Uncertainty in Income Taxes" (FIN 48), which attempts to set out a consistent framework for preparers to use to determine the appropriate level of tax reserves to maintain for uncertain tax positions. This interpretation of FASB Statement No. 109 uses a two-step approach wherein a tax benefit is recognized if a position is more-likely-than-not to be sustained. The amount of the benefit is then measured to be the highest tax benefit which is greater than fifty percent likely to be realized. FIN 48 also sets out disclosure requirements to enhance transparency of an entity's tax reserves. The Company will be required to adopt this Interpretation as of January 1, 2007. The Company is still evaluating the impact of the adoption of FIN 48.

In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157, "Fair Value Measurements" (SFAS 157), which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and requires additional disclosures about fair value measurements. SFAS 157 aims to improve the consistency and comparability of fair value measurements by creating a single definition of fair value. The Statement emphasizes that fair value is not entity-specific, but instead is a market-based measurement of an asset or liability. SFAS 157 upholds the requirements of previously issued pronouncements concerning fair value measurements and expands the required disclosures. This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, however earlier application is permitted provided the reporting entity has not yet issued financial statements for that fiscal year. The Company does not believe that the adoption of SFAS 157 will have a material effect on its consolidated financial statements.

In September 2006, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 108 (SAB 108). SAB 108 was issued to provide interpretive guidance on how the effects of the carryover reversal of prior year misstatements should be considered in quantifying a current year misstatement. The provisions of SAB 108 are effective for the Company for its December 31, 2006 year-end. The adoption of SAB 108 had no impact on the Company's consolidated financial statements.

41

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities", including an amendment of FASB Statement No. 115 SFAS 159. This pronouncement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. The impact of adopting SFAS 159 on the Company's consolidated financial statements, if any, has not yet been determined.

X. Conclusion

The overall performance in year 2006 was outstanding. As a public Company orientated at pharmaceutical industry, we put effort to product innovation. We understand, without sustainable R&D, the medical progress and accessibility to end-user can not fully be realized. In this regard, China Pharma will continue to actively engage with the development and distribution of high-quality products to the market.

BUSINESS

Principal Products and Services

Helpson's primary business is the manufacturing, marketing and sales of pharmaceuticals. Helpson manufactures and markets products in three major categories: cardiovascular and cerebrovascular medicine, raw materials for surface wound, and anti-infection medicine.

At present, Helpson is manufacturing a total of 17 drugs, among which the following four kinds of medicines have received new drug certifications:

- o Buflomedil Hydrochloride tablets, Buflomedil Hydrochloride for injections, Buflomedil Hydrochloride injections, Buflomedil frozen powder aricula and raw materials: Buflomedil Hydrochloride: Used in peripheral blood vessel disease, intermission walk lamely Renaud syndrome, blood vessel convulsion, etc., vascular dementia
- o Naproxen Sodium and Pseudoephedrine Hydrochloride Sustained Release Tablets: anti-flu medicine in the market mixed with pseudoephedrine hydrochloride with a non-drowsy formula and a runny nose suppressant which temporarily relieves cold, sinus and flu symptoms.
- o Roxithramycin dispersible tablets: Pharyngitis and tonsillitis caused by the suppurative chain coccus, nasal sinusitis, otitis media, acute bronchitis, chronic bronchitis due to the acute sensitive fungus break out, pneumonia mycoplasma or pneumonia due to the original body of pneumonia chlamyiae; Urethritis that the original body of chlamyiae of trachoma causes and palate neck inflammation; bacterial infection of the soft tissue of skin.
- o Cefaclor dispersible tablets: Used in otitis media, when the airway is infected, the urethra is infected, or skin and skin tissue are infected.

In addition to the above new medicines, Helpson is manufacturing the following medicines:

- o Gastrodin Injection: Used in neurasthenia, neurasthenia syndrome and traumatic syndrome of the brain; Vertigo; Neuralgia; Headache; etc.
- o Hepatocyte Growth-promoting Factor for Injection: Used to assist and treat various heavy-duty virus hepatitis (acute, subnormal temperature, and chronic serious disease in the early or middle stage of hepatitis)
- o Propylgallate for Injection: Used for preventing and treating cerebral thrombosis, coronary heart disease, and complication after the surgery - thrombus deep phlebitis, etc.
- o Ozagrel Sodium for Injection: Used to treat acute cerebral infarction and kinesipathy accompanied by cerebral infarction.
- o Alginic Sodium Diester Injection: Used in ischemic heart, cerebrovascular diseases (cerebral thrombosis, cerebral embolism, coronary heart disease, etc.) and high lipoprotein blood disease
- o Granisetron Hydrochloride Injection: Post-Operative Nausea and Vomiting, Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting, Prevention of Post-Operative Nausea and Vomiting

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

- o Cerebroprotein Hydrolysate Injection: For the improvement of the symptom of sequela of craniocerebral traumatism and cerebrovascular diseases accompanied by memory decline and attention deficit disorder.
- o Cefaclor dispersible tablets: Used in otitis media, when the airway is

42

infected, the urethra is infected, or skin and skin tissue are infected.

- o Clarithromycin Granules and Clarithromycin Capsules: Suitable for nasopharynx that is infected by one carat of mould plain sensitive mushrooms, airway infection, soft skin tissue infection, otitis media acuta, primary atypical pneumonia, urethritis and cervicitis caused by chlamydia trachomatis,. Used in legion fungus infections or is jointly used in the treatment of the bacillus of mycobacterium avium was infected, spiral shell's bacillus of pylorus infected with other medicines.
- o Chuanxinlian Tablets: Clears away heat and detoxifies, is antibacterial and diminishes inflammation. Used in upper airway infection, bacillary dysentery.
- o Thymopolypeptides Injection: Use for treating various primary or secondary T cell defective disease, immune system diseases, assists and treats the diseases and tumors of various cells with low immunological function.
- o Cefalexin Capsules: Suitable for acute tonsillitis due to the sensitive funguses, airway infection, urine infections, or infection of the angina, otitis media, nasal sinusitis, bronchitis, pneumonia, etc. and when the skin soft tissue is infected
- o Haizhu Oral Liquid: Chinese traditional medicine used in supplementary treatment of high lipoprotein blood disease.

In addition, Helpson's products include a Recombinant Human Ciliary Neutrophic Factor, which is used as a raw material for cosmetics and has the function of wound repairing, including damages caused by ultraviolet rays, acne, analeptic organized by the skin, or citric acid.

There are 20 drugs undergoing research and development including Huguang Keli, Troxerutin and Cerebroprotein Hydrolysate for Injection, Yimaikang Capsule, Bumetnide for Injection, Tiopronin, Omeprazole for Injection, Ceftriaxone Sodium and Tazobactam Sodium, Donepezil Dispersible Tablets, Mycophenolate Mofetil Granules, Cattle Encephalon Glycoside and Ignotin, Clindamycin Phosphate for Injection, Thymopetidium for Injection, Compand Diclofenac Sodium Injection, ShengQing Pian, rhCNTF, Pioglitazone HCL + metformin HCL, ACTOplus, Xinlin Tablets, Xinlin Oral Solution, rhaFGF and Cefprozil Tablets.

Due to the nature of the biotechnology and pharmaceutical industries, the Company continually strives to change its product portfolio to respond to changes in market demand. Helpson traditionally focused on R&D and marketing of cardiovascular and cerebrovascular medicine medicines. Recently, Helpson launched PuSenOK, an anti-flu medicine in the market mixed with pseudoephedrine hydrochloride that has a non-drowsy formula and a runny nose suppressant. Helpson's PuSenOK has passed clinical experiments and entered the trial

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

production stage, and has been awarded the new medicine certificate.

Helpson also plans to expand its biotechnology product series. Based upon the foundation established by Helpson's Neurotrophicpeptide, Helpson will launch several additional biological medicines, including brain peptide injections, and injected Hepatocyte Growth-promoting Factors.

43

Helpson adjusts the delivery system and marketing for each of its products based on the product's target patient group. Maintaining a variety of delivery systems (e.g. tablet, injection, powder, etc.) targeted for different groups enhances Helpson's competitive position in the market. Helpson's present types of delivery include covered tablet, capsule, troche, oral fluid, injection, frozen powder, acicula, and germ-free powder acicula.

Principal Markets

The principal markets of Helpson lie within China. China has the world's largest population of nearly 1.3 billion people. The pharmaceutical industry accounts for approximately 3% of China's annual GDP (Source:<http://www.chinability.com/2004%20economic%20performance.htm>). In 2004, PRC's pharmaceutical industry realized sales of RMB347.6 billion (approximately \$44.56 billion) and net profits of RMB30.64 billion (approximately \$3.93 billion); a 17.44% increase in realized sales and 11.74% increase in net profits from the previous year (Source:<http://www.chinapharm.com.cn>). In 2005, PRC's pharmaceutical industry kept a rising tendency and a steady improvement. In the whole year the industry realized sales of RMB426.54 billion (approximately \$54.68 billion) and net profits of RMB402 billion (approximately \$51.53 billion); a 27% increase in realized sales and 26.53% increase in net profits from the previous year. (<http://www.okokok.com.cn/Shop/Class11/200604/7546.html>) It is estimated that China's pharmaceutical industry will maintain at least a 12%-15% growth rate through the year 2010 (Source: <http://www.511511.com/A1/200501/A100000391720050104093750375.shtml>).

The predicted growth is based upon the relaxation of trade barriers following China's accession to the World Trade Organization, advances in China's economy, and China's large, aging population.

Detailed Market Sectors

Reepitheliazation/Wound rehabilitation medications: These products belong to a new and advanced classification of drugs used to speed the rehabilitation of a wide variety of wounds ranging from lacerations and burns to injuries sustained during childbirth and surgery. Cardiovascular & Cerebrovascular Disease medications: Cardiovascular & cerebrovascular diseases have become increasingly common and have a serious impact on people's health. The SFDA estimated the market share in 2003 of these two medicines in the PRC to be 14.36% of the \$5.1 billion (RMB42.2 billion) market. (Source: <http://www.specc.com.cn/hydt/ShowHydt.aspx?id=121>)

Over-the-Counter Cold & Flu medicines: In 2003, the OTC medicine market capacity in the PRC was approximately \$3.6 billion, (Source: http://www.cnm21.com/xinwen2/041028_007.htm) with cold & flu medicines having a market of RMB2.5billion (Source:

<http://www.fx120.net/yysj/ypsc/scfx/200406101631184449.htm>). The sales of such medicines make up 8.3% of total Over-the-Counter medicine retail sales.

Anti-infection medicines: In the past few years, Anti-bacterial medicines have become the best selling drugs within the PRC while also maintaining a growth rate of 20%. In 2001, the sales reached roughly RMB30 billion (approximately \$3.85 billion); in 2003, the sales reached more than RMB40 billion (approximately \$5.13 billion), achieving a 30% market share. (Source: SFDA Prospectus of Zhejiang Jingxin Pharmaceutical Co., Ltd.).

Distribution

Helpson's products are currently sold in 29 provinces, sovereignties, and autonomous regions. Helpson has 16 sales offices and approximately 626 sales agents in China.

Helpson uses a flat distribution channel system of independent regional distributors. In a typical distribution contract, a distributor will be provided with certain sales targets for a particular period according to a set retail price. If the distributor completes the sales task within the prescribed period, the agent distributor will be given greater economic incentives and future distribution opportunities. If the distributor fails to complete the sales task within the prescribed period, Helpson will cancel its contract with the distributor and sign with other competent distributors. Helpson also signs reselling contracts with franchise drug companies for the distribution of its products. The franchise drug company, as a reseller, resells the Company's products to local hospitals, drug stores, and other channel distributors. In addition, Helpson sells its products directly to hospitals and retail drugstores.

Industry Background and Competition

The pharmaceutical industry accounts for approximately 3% of China's GDP. (Source: <http://blog.fh21.com.cn/post/65/106>). The industry's primary categories include chemical medicine, traditional Chinese medicinal material, traditional Chinese medicinal film, prepared Chinese herbal medicine, antibiotics, biological products, biological medicine, radioactive medicine, medical appliances, sanitation materials, pharmaceutical machinery, medical packaging, and trading.

The pharmaceutical industry in China is fragmented with many drug manufacturers. According to the SFDA-reported statistics, in July of 2004, there were 5071 manufacturing pharmaceutical companies (not including companies producing traditional Chinese medicinal film, medical oxygen, reagent of in-vitro diagnosis or supplementary materials). The total market share of the top 10 biggest companies was about 42%, compared to 66% in the US. (Source: SFDA (pound) Prospectus of Zhejiang Jingxin Pharmaceutical Co., Ltd.)

Competition in the pharmaceutical industry is reduced by barriers to entry. A company wishing to enter the industry must comply with the standards and regulations set forth by the government. In the PRC, the SFDA is the authority that monitors and supervises the administration of the pharmaceutical industry

including pharmaceutical products, medical appliances, and equipment. Pharmaceutical manufacturing enterprises must obtain a Pharmaceutical Manufacturing Enterprise Permit issued by the relevant pharmaceutical administrative authorities and relevant health departments at the provincial level where the enterprise is located. Furthermore, all pharmaceutical products produced in the PRC, with the exception of Chinese herbal medicines in soluble form, must bear a registered number approved by the appropriate governmental authorities in the PRC. Lastly, in accordance with the World Health Organization, the PRC now requires compliance with GMP standards in pharmaceutical production in order to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing final products. As the regulatory approval process becomes more stringent, it also increases the barriers to entering the market.

Due to the variety of consumer demands within the pharmaceutical market, pharmaceutical companies have relatively dispersed product lines. We have identified, however, two primary strategies we must adopt in order to stay competitive. In expanding market share of common traditional medicine, we must take advantage of 1) our large manufacturing scale and reasonable cost control mechanisms, and 2) our strong sales network.

Description of Property

Helpson owns a factory with a floor area of 663.94 square meters located at the East Wing, 6/F, 5 Jianshe Road, Jinpan Industrial Development Zone, Haikou.

Helpson also owns the land use rights to another 31,050 square meters located at plot C09-2, Hainan Bonded Zone, Haikou. Helpson built a factory with a floor area of approximately 7,300 square meters on this parcel.

In addition, Helpson entered into a lease agreement with Hainan Zhongfu Going-abroad Personnel Service Center ("Zhongfu"), under which Helpson rented the offices located at 2/F, Jiahai Building owned by Zhongfu as its principal executive offices. The term of the lease is 10 years, from November 21, 2000 to November 20, 2010. The rent from November 21, 2000 to November 20, 2005 is RMB3,600 per month. The rent from November 21, 2005 to November 20, 2010 may be adjusted within 5% of the original rent.

Intellectual Property

Helpson owns 13 registered trademarks and logos used in connection with western medicine, raw material medicine, Chinese herbal medicine and medicine injections, which are: Funalin, Fukexing, Helpson, Beisha, Shiduotai, Xinuo and the HPS logo, as well as five other logos as listed in the Schedule 4.6 of the current report filed as of October 20, 2005; one logo used in connection with bathing cosmetics, shampoo, hair stimulating shampoo, facials, nail polish, cosmetics, perfume, perfume essence oils, skin care toner, and cosmetics cleansers; one registered trademark, Helpson; and one logo, used in connection with medical appliances and equipment, surgical implants, surgical implanted artificial eyes, surgical artificial crystalline lens, surgical artificial skin,

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

and artificial eyes. In addition, Helpson is applying for registration of nine other trade marks used in connection with western medicine, raw material medicine, Chinese herbal medicine and medicine injections.

Helpson owns the intellectual property rights of its genetic engineering technology for rh-CNTF and rh-aFGA, and fungi form engineering and production techniques.

Employees

As of March 29, 2007, the Company had 123 regular employees. Helpson is also aided by the efforts of a 55-member outside sales and marketing team.

Government Regulation

The following is a summary of the principal governmental laws and regulations that are or may be applicable to pharmaceutical manufacturing companies like Helpson in China. The scope and enforcement of many of the laws and regulations described below are uncertain. We cannot predict the effect of further developments in the Chinese legal system, including the promulgation of new laws, changes to existing laws, or the interpretation or enforcement of laws.

The major pieces of legislation regarding the pharmaceutical industry include the Law of Drug Administration of the PRC, effective as of December 1, 2001, its Implementing Regulations effective as of September 15, 2002, and the Administrative Measures of Drug Registration effective as of May 1, 2005.

Production Licenses

In the PRC, SFDA is the authority that monitors and supervises the administration of the pharmaceutical industry including pharmaceutical products and medical appliances and equipment. Any pharmaceutical manufacturing enterprise must obtain a Pharmaceutical Manufacturing Enterprise Permit issued by the relevant pharmaceutical administrative authorities and relevant public health departments at the provincial level where the enterprise is located.

Registration of Pharmaceutical Products

All pharmaceutical products that are produced in the PRC must bear a registered number approved by the SFDA in the PRC, with the exception of Chinese herbs and Chinese herbal medicines in soluble form. The medicine manufacturing enterprises must obtain the medicine registration number before manufacturing any medicine.

GMP

The World Health Organization encourages the adoption of GMP standards in pharmaceutical production in order to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing final

products. In 1998, the Ministry of Health of the PRC started to issue GMP standards for the pharmaceutical manufacturing enterprises in the PRC. Any pharmaceutical manufacturing enterprise must comply with GMP standards by the end of June 30th, 2004. The process of GMP authorization requires about three months.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Examination and Approval of New Medicines

New medicines generally refer to those that have not yet been marketed in the PRC. Marketed medicines changing the type or application method, or adding new therapeutic functions shall also be treated as new medicines.

According to the Administrative Measures of Drug Registration, the approval of new medicine shall undergo the following procedures:

The applicant shall first carry out clinical trials, which consists of four phases.

Upon completion of the clinical trial, the applicant shall submit the Medicine Registration Application Form, clinical trial materials and other supplementary materials to the provincial medicine administration authority where the applicant is located. In the meantime, the applicant submits raw materials of the medicine to the China Medicine and Biological Products Examination Institute (the "Institute").

The provincial medicine administration authority will conduct a preliminary examination of the application. If it decides to accept the application, it will conduct an on-site examination of the application and draw sample products within five days of accepting the application. The provincial medicine administration authority will then send the samples to the medicine inspection institute for inspection, which shall submit its inspection report to the SFDA with a copy to the provincial medicine administration authority.

The provincial medicine administration authority will submit its examination opinion, examination report and application materials to the SFDA, which will perform a comprehensive examination of the application. If the SFDA deems the application complete, it will issue the Medicine Registration Certificate and New Medicine Certificate to the applicant. If the applicant already holds a Medicine Manufacturing Permit, the SFDA will issue the Medicine Registration Number at the same time.

Legal Proceedings

We have no pending legal proceedings. From time to time, we may be involved in various claims, lawsuits, disputes with third parties, and actions involving allegations of breach of contract or product liability actions incidental to the normal business operations.

MANAGEMENT

The following table sets forth the names of all of our current directors and executive officers to be appointed. The directors will serve until the next annual meeting of the stockholders or until their successors are elected or appointed and qualified. Executive officers will serve at the board's discretion.

Name	Age	Position
------	-----	----------

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Heung Mei TSUI	50	Director
Zhilin LI	54	Director, President and Chief Executive Officer
Xinhua WU	44	Director and Chief Financial Officer
Jian YANG	52	Secretary

Ms. Heung Mei TSUI. Ms. Tsui is director of the Company since October 19, 2005. She is a self-employed business woman engaged in the re-export business, including chemical products trade and electromechanical products trade. She is also Toyota automobile's agent in Hainan province. She graduated from Huanan Financial & Economic College in 1982.

Ms. Zhilin LI: Ms. Li is director, President and Chief Executive Officer of the Company. She is a founder of Helpson, and has served as chairman and CEO of Helpson since 1993. Ms. Li was formerly the president of Haikou Bio-engineering institute, and the vice president of the Sichuan Institute of Biology. She graduated from Sichuan University, where she majored in biology, and later became an instructor.

Mr. Xinhua WU: Mr. Wu is director and Chief Financial Officer of the Company. He has acted as CFO of Helpson since his hiring in 1999. Mr. Wu served as CFO and assistant to the CEO at Hainan Guobang Enterprises Inc., where he was employed from 1992 to 1999. Mr. Wu graduated from the University of Wales with an MBA degree and Jiangxi Financial college with a Bachelor of Science degree in Finance.

Ms. Jian YANG: Ms. Yang is Secretary of the Company since October 19, 2005. She is a founder and director of Helpson. Ms. Yang was a technician at the Sichuan Institute of Biology in 1990 and vice president of Haikou Biomedicine Engineering Co., Ltd. in 1991 Ms. Yang earned her MBA at the University of Wales, England.

Board Composition and Committees

The board of directors are currently composed of Heung Mei Tsui, Zhilin Li and Xinhua Wu. All board actions require the approval of a majority of the directors in attendance at a meeting at which a quorum is present.

49

We currently have no committees of Audit, Compensation, or any other committees; therefore, the board will act in the capacity of the absent committees. As a result, each of the directors is not independent with respect to all members of the board of directors applying relevant committee independence standards.

Disclosure of Commission Position of Indemnification for Securities and Liabilities

Our Amended and Restated Certificate of Incorporation, with certain exceptions, eliminates any personal liability of directors or officers to us or our stockholders for monetary damages for the breach of such person's fiduciary duty to the extent permitted by law. We have also adopted by-laws which provide for indemnification to the full extent permitted under the law which includes all

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

liability, damages, costs, or expenses arising from or in connection with service for, employment by, or other affiliation with us to the maximum extent and under all circumstances permitted by law.

There are presently no material pending legal proceeding to which a director, officer, or employee of ours is a party. There is no pending litigation or legal proceeding involving one of our directors, officers, employees or other agents as to which indemnification is being sought, and we are not aware of any pending or threatened litigation that may result in claims for indemnification by any director, officer, employee or other agent.

To the extent provisions of our Amended and Restated Certificate of Incorporation provide for indemnification of directors for liabilities arising under the Securities Act or the Exchange Act, those provisions are, in the opinion of the Securities and Exchange Commission, against public policy and therefore are unenforceable.

Code of Ethics

We do not yet have a code of ethics. Due to the recent completion of the Second Round Financing, the board of directors has decided to postpone the adoption of a code of ethics until we are able to focus our business plan and develop a greater infrastructure. Once we have adopted a Code of Ethics, a copy may be obtained by sending a written request to our corporate Secretary.

DIRECTOR AND EXECUTIVE COMPENSATION

No cash compensation was paid to our director for services as a director during the fiscal year ended December 31, 2006. We have no standard arrangement pursuant to which our board of directors is compensated for their services in their capacity as directors. The board of directors may award special remuneration to any director undertaking any special services on behalf of our Company other than those services ordinarily required of a director. All authorized out-of-pocket expenses incurred by a director on our behalf will be subject to reimbursement upon our receipt of required supporting document of such expenses. No director received and/or accrued any compensation for his services as a director, including committee participation and/or special assignments.

50

The following table provides compensation information for the period indicated with respect to the person who served as our president for the years ended December 31, 2006, 2005 and 2004, and all other of our executive officers receiving total salary and bonus in excess of \$100,000 during the years ended December 31, 2006, 2005 and 2004 (collectively, the "Named Executive Officers"):

SUMMARY COMPENSATION TABLE

	Annual Compensation				Long Term Compensation Awards		Payou
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Name and Principal Position	Year	Salary (\$)	Bonus (\$)	Other Compensation	Annual Restricted Stock Awards (\$)	Securities Under-lying Options/ SARs (#)	LTI Payou (\$)
(1) Zhilin LI Director, CEO and President	2006	-	-	-	-	-	-
	2005	18,007	-	-	-	-	-
(2) Keith P. Boyd CEO, CFO & President	2005	-	-	-	-	-	-
	2004	-	-	-	-	-	-
(2) Tim Halter President, CEO, CAO, Treasurer and Secretary	2005	-	-	-	-	-	-

(1) Zhilin LI has been our CEO and president since October 20, 2005 and her salary was paid in RMB. As of January 20, 2006, Zhilin LI was elected as the director of the Company. Her salary in the fiscal year ended December 31, 2006 has not been paid as of the date of this Prospectus.

(2) Prior to October 20, 2005, Keith P. Boyd and Tim Halter did not spend any material time working since we had no material business then. Accordingly, we did not compensate any officer or director during this time period.

Stock Option Grants and Exercises

We currently have no option, retirement, pension, or profit sharing programs for the benefit of the directors, officers or other employees, but the board of directors may recommend adoption of one or more such programs in the future.

Employment, Severance and Change of Control Agreements

51

Ms. Zhilin Li entered into an Employment Agreement with Helpson, which provides that Ms. Li is employed by Helpson to perform executive management. The term of her employment is from July 1, 2005 to June 30, 2010. Her annual salary is RMB800,000 or approximately \$100,000. Mr. Xinhua Wu was employed by Helpson to act as its CFO. The term of his employment is from July 1, 2005 to June 30, 2010. His annual salary is RMB500,000 or approximately \$62,500. Ms. Jian Yang was employed by Helpson to act as its Deputy General Manager. The term of her employment is from July 1, 2005 to June 30, 2010. Her annual salary is RMB500,000 or approximately \$62,500. Ms. Zhilin Li was paid RMB 150,000 (approximately US\$18,007) as the compensation for acting as the Company's director, CEO and president during the fiscal year ended June 30, 2005. Mr. Xinhua Wu and Ms. Jian Yang received no compensation for acting as officers during the fiscal year ended June 30, 2005. Ms. Zhilin Li, Mr. Xinhua Wu and Ms. Jian Yang has not received any compensation for acting as officers during the fiscal year ended December 31, 2006 until the date of this Prospectus.

RELATIONSHIPS AND RELATED TRANSACTIONS

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

None.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information known to us with respect to the beneficial ownership of our common stock as of March 27, 2006 and (i) all persons who are known to us to be beneficial owners of five percent or more of the common stock, (ii) each of our Directors, and (iii) all current Directors and executive officers as a group.

NAME AND ADDRESS OF BENEFICIAL OWNER (1)	SHARES BENEFICIALLY OWNED	% OF CLASS OWNED
Heung Mei Tsui	15,278,385	41.04
Zhilin Li	10,000,000	26.86
All Directors and Executive Officers as a Group	25,278,385	67.9

(1) Unless otherwise stated, the address of all persons in the table is 2nd Floor, No.17, Jinpan Road, Kaikou, Hainan Province, China.

Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting or investment power with respect to the securities. Unless otherwise indicated, the address for each of the individuals listed in the table is care of Hainan Helpson Bio-Pharmaceutical Co. Ltd, 2nd Floor, No.17, Jinpan Road, Kaikou, Hainan Province, China.

Unless otherwise indicated by footnote, the persons named in the table have sole

52

voting and sole investment power with respect to all shares of common stock shown as beneficially owned by them, subject to applicable community property laws. Percentage of beneficial ownership is based on 37,228,938 shares of our common stock outstanding as of March 29, 2007.

SELLING SECURITY HOLDERS

We have prepared this Prospectus to allow the selling stockholders or their pledgees, donees, transferees or other successors in interest, to sell up to 3,758,823 shares of our common stock. All of the common stock offered by this Prospectus is being offered by the selling stockholders for their own accounts.

2006 Private Placement

On February 1, 2007, we completed an offering pursuant to a Subscription and Registration Rights Agreement with 17 Investors in connection with a private placement of 2,505,882 shares of the Company's common stock at \$1.70 per share. Pursuant to the Agreement, the Investors also received three-year warrants to purchase an aggregate of 1,252,941 shares of Company's common stock at \$2.38 per share. Pursuant to the transaction on February 1, 2007, we received the subscription proceeds in the aggregate amount of \$4,259,900. The net proceeds,

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

after deduction of related expenses, amounted to \$3,814,642.

The following table sets forth the names of the selling stockholders and for each selling stockholder the number of shares of common stock beneficially owned as of March 29, 2007 and the number of shares being registered. Each selling stockholder acquired its securities in the Company's secondary private placements of securities completed on February 1, 2007. Furthermore, none of the selling stockholders has held a position as an officer or director of the company, nor has any selling stockholder had a material relationship of any kind with the company. We will not receive any proceeds from the resale of the common stock by the selling stockholders. We will, however, receive proceeds from the exercise of warrants to purchase 1,252,941 shares of common stock if such warrants are exercised.

Name	Number of Shares of Common Stock Beneficially Owned Prior to the Offering	Number of Shares Offered Pursuant to this Prospectus	Sha Be Aft
Squires Family LP (2)	300,000	300,000	
Whitebox Intermarket Partners L.P. (3)	441,176	441,175	
Harborview Master Fund L.P. (4)	150,000	150,000	
Midsouth Investor Fund LP(5)	264,707	264,706	
53			
Midsouth Investment Management LLC (6)	88,236	88,236	
Halter Pope USX China Fund (7)	600,000	600,000	
Guerilla Partners LP (8)	110,294	110,294	
Hua-Mei 21st Century Partners, LP(9)	110,294	110,294	
Pope Investments LLC(10)	450,000	450,000	
Kensington Partners, LP(11)	286,740	286,740	
Bald Eagle Fund, Ltd.(12)	13,260	13,260	
Silver Rock I, Ltd(13)	150,000	150,000	
Professional Offshore Opportunity Fund, Ltd.(14)	220,587	220,587	
Nite Capital LP(15)	352,941	352,941	
Topwin Trading (H.K.) Company Limited.(16)	88,236	88,236	
HongKong Shun Ho Investment Group Limited(17)	44,118	44,118	
Iroquois Master Fund, Ltd. (18)	88,236	88,236	
TOTAL SHARES OFFERED		3,758,823	

- (1) Assumes that all shares of common stock registered will be sold and that all shares of common stock underlying warrants will be issued and sold.
(2) Represents: (a)200,000 shares of common stock purchased in the Second Round

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

- Financing; and (b) 100,000 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (3) Represents: (a) 294,117 shares of common stock purchased in the Second Round Financing; and (b) 147,058 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
 - (4) Represents: (a) 100,000 shares of common stock purchased in the Second Round Financing; and (b) 50,000 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
 - (5) Represents: (a) 176,471 shares of common stock purchased in the Second Round Financing; and (b) 88,235 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
 - (6) Represents: (a) 58,824 shares of common stock purchased in the Second Round Financing; and (b) 29,412 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
 - (7) Represents: (a) 400,000 shares of common stock purchased in the Second Round Financing; and (b) 200,000 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.

54

- (8) Represents: (a) 73,529 shares of common stock purchased in the Second Round Financing; and (b) 36,765 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (9) Represents: (a) 73,529 shares of common stock purchased in the Second Round Financing; and (b) 36,765 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (10) Represents: (a) 300,000 shares of common stock purchased in the Second Round Financing; and (b) 150,000 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (11) Represents: (a) 191,160 shares of common stock purchased in the Second Round Financing; and (b) 95,580 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (12) Represents: (a) 8,840 shares of common stock purchased in the Second Round Financing; and (b) 4,420 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (13) Represents: (a) 100,000 shares of common stock purchased in the Second Round Financing; and (b) 50,000 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (14) Represents: (a) 147,058 shares of common stock purchased in the Second Round Financing; and (b) 73,529 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (15) Represents: (a) 235,294 shares of common stock purchased in the Second Round Financing; and (b) 117,647 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (16) Represents: (a) 58,824 shares of common stock purchased in the Second Round

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

- Financing; and (b) 29,412 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (17) Represents: (a) 29,412 shares of common stock purchased in the Second Round Financing; and (b) 14,706 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.
- (18) Represents: (a) 58,824 shares of common stock purchased in the Second Round Financing; and (b) 29,412 shares of common stock issuable upon exercise of warrants with an exercise price of \$2.38 per share with an expiration date of February 1, 2010 purchased in our Second Round Financing.

55

DESCRIPTION OF SECURITIES

The descriptions in this section and in other sections of this Prospectus of our securities and various provisions of our Certificate of Incorporation and our Bylaws are limited solely to descriptions of the material terms of our securities, Articles of Incorporation and Bylaws. Our Amended and Restated Certificate of Incorporation and Bylaws have been filed with the SEC as exhibits to our registration statement of which this Prospectus forms a part.

Common Stock

The authorized common stock of the Company consists of 60,000,000 shares, \$0.001 par value per share (the "Common Stock"). As of the date of this Prospectus, approximately 37,228,938 shares of Common Stock were issued and outstanding. The holders of our common stock are entitled to equal dividends and distributions per share with respect to the common stock when and if declared by the Board of Directors from funds legally available therefore. No holder of any shares of our common stock has a preemptive right to subscribe for any of our securities. Upon liquidation, dissolution, or winding up of us, and after payment of creditors and preferred stockholders, the assets will be divided pro-rata on a share-for-share basis among the holders of the shares of common stock. All shares of common stock now outstanding are fully paid, validly issued, and non-assessable.

Each share of common stock is entitled to one vote with respect to the election of any director or any other matter upon which stockholders are required or permitted to vote. Holders of the common stock do not have cumulative voting rights, so the holders of more than 50% of the combined shares voting for the election of directors may elect all of the directors if they choose to do so, and, in that event, the holders of the remaining shares will not be able to elect any members to the board of directors.

Anti-Takeover Effects of Various Provisions of Delaware Law and Our Articles of Incorporation and Bylaws

We are subject to Section 203 of the Delaware General Corporation Law. Subject to certain exceptions, this statute regulating corporate takeovers prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for three years following the date that the stockholder became an interested stockholder.

Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested

stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation's outstanding voting securities. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may discourage takeover attempts that might result in a premium over the market price for the shares of common stock held by stockholders.

56

Provisions of our Certificate of Incorporation and Bylaws may have the effect of making it more difficult for a third party to acquire, or discourage a third party from attempting to acquire, control of our Company by means of a tender offer, a proxy contest or otherwise. These provisions may also make the removal of incumbent officers and directors more difficult. These provisions are intended to discourage certain types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock. These provisions may make it more difficult for stockholders to take specific corporate actions and could have the effect of delaying or preventing a change in control.

Shares Eligible for Future Sale

On March 29, 2007, 37,228,938 shares of our common stock were outstanding. Of the outstanding shares, 7,628,768 shares of common stock are immediately eligible for sale in the public market without restriction or further registration under the Securities Act. All other outstanding shares of our common stock are "restricted securities" as such term is defined under Rule 144, in that such shares were issued in private transactions not involving a public offering and may not be sold in the absence of registration other than in accordance with Rules 144, 144(k), or 701 promulgated under the Securities Act or another exemption from registration.

In general, under Rule 144 as currently in effect, a person, including an affiliate, who has beneficially owned shares for at least one year is entitled to sell, within any three-month period commencing 90 days after the date of this Prospectus, a number of shares that does not exceed the greater of one percent of the then outstanding shares of our common stock or the average weekly trading volume in our common stock during the four calendar weeks preceding the date on which notice of such sale is filed, subject to various restrictions. In addition, a person who is not deemed to have been an affiliate of ours at anytime during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least two years would be entitled to sell those shares under Rule 144(k) without regard to the requirements described above. To the extent that shares were acquired from an affiliate, such person's holding period for the purpose of affecting a sale under Rule 144 commences on the date of transfer from the affiliate.

There has been very limited trading volume in our common stock to date. Sales of substantial amounts of our common stock under Rule 144, this Prospectus, or otherwise, could adversely affect the prevailing market price of our common stock and could impair our ability to raise capital through the future sale of our securities.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Transfer Agent and Registrar

The Transfer Agent and Registrar for our common stock is Securities Transfer Corporation, 2591 Dallas Parkway, Suite 102, Frisco, Texas 75234 and its telephone number is 469.633.0100.

57

PLAN OF DISTRIBUTION

We are registering a total of 3,758,823 shares of our common stock, including 1,252,941 shares of common stock issuable upon exercise of outstanding warrants, that are being offered by the selling stockholders. As used in this Prospectus, "selling stockholders" includes the pledgees, donees, transferees or others who may later hold the selling stockholders' interests in the common stock. We will pay the costs and fees of registering the common shares, but the selling stockholders will pay any brokerage commissions, discounts or other expenses relating to the sale of the common stock. We will not receive the proceeds from the sale of the common stock by the selling stockholders. We will, however, receive proceeds from the exercise of warrants to purchase shares of common stock.

The selling stockholders and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their shares of common stock on any stock exchange, market, or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may use any one or more of the following methods when selling shares:

- Ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
- Block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
- Purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
- An exchange distribution in accordance with the rules of the applicable exchange;
- Privately negotiated transactions;
- Broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;
- A combination of any such methods of sale; and
- Any other method permitted pursuant to applicable law.

The selling stockholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this Prospectus. Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved.

The selling stockholders may from time to time pledge or grant a security interest in some or all of the shares of common stock or warrants owned by them and, if they default in the performance of their secured obligations, the pledges, or secured parties may offer and sell the shares of common stock from

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

time to time under this Prospectus, or under an amendment to this Prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending the list of selling stockholders to include the pledgee, transferee, or other successors in interest as selling stockholders under this Prospectus.

58

LEGAL MATTERS

The validity of the registration for the resale of common stock will be passed upon for us by King & Wood LLP.

EXPERTS

Hansen, Barnett & Maxwell, P.C., independent registered public accounting firm, has audited, as set forth in their report thereon appearing elsewhere herein, our consolidated financial statements at December 31, 2006 and 2005 and for the year ended December 31, 2006 and the period from January 12, 2005 (date of inception) through December 31, 2005 that appear in the Prospectus. The financial statements referred to above are included in this Prospectus with reliance upon the independent registered public accounting firm's opinion based on their expertise in accounting and auditing.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We have filed with the SEC a registration statement on Form SB-2 under the Securities Act in connection with the offering of the common stock by the selling stockholders. This Prospectus, which is part of the registration statement, does not contain all of the information included in the registration statement. Some information is omitted and you should refer to the registration statement and its exhibits. With respect to references made in this Prospectus to any contract, agreement or other document of ours, such references are not necessarily complete and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document.

We are subject to the informational requirements of the Securities Exchange Act of 1934 which requires us to file reports, proxy statements and other information with the Securities and Exchange Commission. Such reports, proxy statements and other information may be inspected at public reference facilities of the SEC at 100 F Street N.E. Washington, D.C. 20549. Copies of such material can be obtained from the Public Reference Section of the SEC at 100 F Street N.E. Washington, D.C. 20549 at prescribed rates. Because we file documents electronically with the SEC, you may also obtain this information by visiting the SEC's internet website at <http://www.sec.gov>.

..

59

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

CHINA PHARMA HOLDINGS, INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm.....	F-2
Consolidated Balance Sheets.....	F-3
Consolidated Statements of Operations.....	F-4
Consolidated Statements of Stockholders' Equity.....	F-5
Consolidated Statements of Cash Flows.....	F-6
Notes to the Consolidated Financial Statements.....	F-7

F-1

HANSEN, BARNETT & MAXWELL, P.C.
A Professional Corporation
CERTIFIED PUBLIC ACCOUNTANTS
5 Triad Center, Suite 750
Salt Lake City, UT 84180-1128
Phone: (801) 532-2200
Fax: (801) 532-7944
www.hbmcpas.com

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and the Shareholders
China Pharma Holdings, Inc.

We have audited the accompanying consolidated balance sheets of China Pharma Holdings, Inc. as of December 31, 2006 and 2005, and the related consolidated statements of operations, stockholders' equity, and cash flows for the year ended December 31, 2006 and for the period from January 12, 2005 (date of inception) through December 31, 2005. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of China Pharma Holdings, Inc. and the results of their operations and their cash flows for the year ended December 31, 2006 and for the period from January 12, 2005 (date of inception) through December 31, 2005, in conformity with accounting principles generally accepted in the United States of America.

HANSEN, BARNETT & MAXWELL, P.C.

Salt Lake City, Utah
March 21, 2007

F-2

CHINA PHARMA HOLDINGS, INC. CONSOLIDATED BALANCE SHEETS

	December 31, 2006

ASSETS	
Current Assets:	
Cash and cash equivalents	\$ 656,441
Trade accounts receivable, less allowance for doubtful accounts of \$1,562,494 and \$1,412,353, respectively	12,101,979
Other receivables, less allowance for doubtful accounts of \$27,517 and \$111,029, respectively	355,554
Deferred offering costs	59,390
Advances to suppliers	2,255,877
Inventory	10,277,887

Total Current Assets	25,707,128

Non-current Assets:	
Property and equipment, net of accumulated depreciation of \$619,645 and \$250,184, respectively	2,725,173
Intangible assets, net of accumulated amortization of \$184,175 and \$135,656, respectively	65,344
Deferred tax assets	16,736

Total Non-current Assets	2,807,253

TOTAL ASSETS	\$ 28,514,381
	=====
LIABILITIES AND SHAREHOLDERS' EQUITY	
Current Liabilities:	
Trade accounts payable	\$ 477,291
Accrued expenses	104,216

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Accrued taxes payable	167,419
Other payables	185,096
Advances from customers	141,871
Accounts payable -related parties	22,650
Short-term notes payable	6,533,649
Dividends payable	-
Total Current Liabilities	7,632,192
Research and development commitments	31,980
Total Liabilities	7,664,172
Stockholders' Equity:	
Common stock, \$0.001 par value, 60,000,000 shares authorized, 34,723,056 shares issued and outstanding	34,723
Additional paid-in capital	7,764,979
Foreign currency translation adjustment	663,871
Retained earnings	12,386,636
Total Stockholders' Equity	20,850,209
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 28,514,381

The accompanying notes are integral part of these consolidated financial statements

F-3

CHINA PHARMA HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS

	For the year ended December 31, 2006	For the period from January 12, 2005 (Date of Inception) through December 31, 2005
Revenue	\$ 21,843,262	\$ 8,657,813
Cost of Revenue	11,745,815	4,166,965
Gross Profit	10,097,447	4,490,848
Operating expenses:		
Selling expenses	260,128	106,129
General and administrative	1,213,828	140,903
Total Operating Expenses	1,473,956	247,032

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Income from Operations	8,623,491	4,243,816
Non-operating income (expenses):		
Interest income	991	769
Interest expense	(145,881)	(186,452)
Other income (expense)	108,485	(6,482)
Total Non-operating Income (Expense)	(36,405)	(192,165)
Income Before Taxes	8,587,086	4,051,651
Income tax expense	-	252,101
Net Income	\$ 8,587,086	\$ 3,799,550
Comprehensive income - foreign currency translation adjustments	563,945	99,926
Comprehensive Income	\$ 9,151,031	\$ 3,899,476
Basic and Diluted Earnings per Common Share	\$ 0.25	\$ 0.34
Weighted-average Common Shares Outstanding	34,723,056	11,289,480

The accompanying notes are integral part of these consolidated financial statements

F-4

CHINA PHARMA HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

	Common Stock Shares	Common Stock Amount	Additional Paid-in Capital	Accumulated Other Comprehensive Income
Balance, January 12, 2005 (Date of Inception)	-	\$ -	\$ -	\$ -
Shares issued for cash, April 12, 2005	85,112	85	(84)	-
Shares issued for cash, August 16, 2005	25,193,273	25,193	3,465,981	-
Shares issued for cash, net October 20, 2005	6,944,611	6,945	4,306,055	-
Shares issued to acquire China				

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Pharma Holdings, Inc., recorded as a purchase	2,500,060	2,500	(6,973)	-
Net income for the year	-	-	-	-
Foreign currency translation adjustment	- #	-	-	99,926
Balance, December 31, 2005	34,723,056	34,723	7,764,979	99,926
Net income for the year	-	-	-	-
Foreign currency translation adjustment	-	-	-	563,945
Balance, December 31, 2006	34,723,056	\$ 34,723	\$ 7,764,979	\$ 663,871

F-5

CHINA PHARMA HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the year ended December 31, 2006	For the period from January 12, 2005 (Date of Inception) through December 31, 2005
Cash Flows from Operating Activities:		
Net income	\$ 8,587,086	\$ 3,799,550
Depreciation and amortization	397,001	250,184
Accretion of discount on notes payable	-	86,060
Changes in assets and liabilities:		
Trade accounts receivable	(6,077,526)	(1,198,199)
Other receivables	42,642	80,164
Advances to suppliers	(61,345)	(916,792)
Inventory	(4,214,702)	(2,395,393)
Deferred tax assets	115,564	(89,763)
Trade accounts payable	(219,427)	383,188
Accrued expenses	86,265	11,330
Accrued taxes payable	(407,744)	356,187
Other payables	(71,759)	(588,748)
Advances from customers	87,612	(226,863)
Net Cash Used in Operating Activities	(1,736,333)	(449,095)

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Cash Flows from Investing Activities:		
Purchase of property and equipment	(182,346)	(433,524)
Purchase of intangible assets	(9,657)	(50,611)
Notes receivable	-	11,277
Net cash received in purchase of Helpson	-	131,336
Net Cash (Used) by Investing Activities	(192,003)	(341,522)
Cash Flows from Financing Activities:		
Payment of dividend payable	-	(237,599)
Payment of note payable	-	(6,317,849)
Proceeds from note payable	2,140,943	-
Proceeds from loan from shareholder	22,650	-
Proceeds from issuance of common stock	-	7,804,175
Payment of offering costs	(58,167)	-
Net Cash Proceeds from Financing Activities	2,105,426	1,248,727
Effect of Exchange Rate Changes on Cash	18,131	3,110
Net Change in Cash	195,221	461,220
Cash and Cash Equivalents at Beginning of Period	461,220	-
Cash and Cash Equivalents at End of Period	\$ 656,441	\$ 461,220

F-6

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

NOTE 1 - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Organization - Onny Investment Limited ("Onny") was incorporated in the British Virgin Islands on January 12, 2005 and was a development stage enterprise through June 15, 2005. On June 16, 2005, Onny acquired all of the outstanding shares of Hainan Helpson Medical & Biotechnology Co., Ltd, a privately held Chinese joint venture ("Helpson") and emerged from the development stage.

On October 19, 2005, Onny was reorganized as a wholly owned subsidiary of China Pharma Holdings, Inc., formerly TS Electronics, (the Company"). The reorganization was accomplished by an exchange of Onny's common shares for 25,278,385 shares of the Company's common stock resulting in a 851-for-1

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

exchange ratio. In addition, the prior Onny convertible preferred shareholders exchanged their shares for 6,944,611 shares of the Company's common stock resulting in a 694-for-1 exchange ratio. The reorganization of Onny into the Company was recognized as a stock split of the common stock of Onny and the effective issuance by Onny of 2,500,060 shares of the Company's common stock in exchange and the assumption of \$4,473 in liabilities. This transaction was accounted for as a reverse acquisition of the Company and was recognized as a non-monetary exchange.

Nature of Operations - Helpson manufactures and markets several Western and Chinese medicines sold mainly to hospitals and private retailers in The People's Republic of China (PRC), through its marketing department located in Hainan Province. There are also nine other offices, with sales representatives in other provinces and cities throughout the PRC. Helpson's other operating activities include biochemical products, health products, and cosmetics.

Accounting Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Consolidation and Basis of Presentation - The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The functional currency of the operating subsidiaries in the PRC is the Chinese Yuan Renminbi (CNY); however, the accompanying financial statements have been expressed in United States Dollars ("USD"). The accompanying consolidated balance sheets have been translated into USD at the exchange rates prevailing at each balance sheet date. The accompanying consolidated statements of operations have been translated using the average exchange rates prevailing during the periods of each statement. See Note 9.

The accompanying consolidated financial statements include the accounts and

F-7

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

operations of Onny from the date of its inception on January 12, 2005 and the accounts and operations of Helpson from the date of its acquisition on June 16, 2005. The accompanying consolidated financial statements have been restated on a retroactive basis for the effects of the stock split resulting from the reorganization of Onny into the Company. All significant inter-company balances and transactions have been eliminated in consolidation.

Fair Values of Financial Instruments - Based on the borrowing rates currently available to the Company for bank loans with similar terms and average maturities, the carrying amounts of notes payable that were outstanding during the current period approximated fair value because of either the immediate or short-term maturity of these financial instruments or because the underlying instruments are at interest rates which approximated current market rates.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Cash and cash equivalents - Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term certificates of deposit with original maturities of three months or less. Cash deposits are held at financial institutions in The Peoples Republic of China and are not insured by the FDIC.

Trade receivables and allowance for doubtful accounts - Trade receivables are carried at original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. It is common practice in China for receivables to extend beyond one year. Included in trade receivables is approximately \$1,265,079 that occurred more than one year from December 31, 2006, but is estimated to still be collectable.

Inventory - Inventories are stated at the lower of cost or net realizable value, on an average cost basis. The method of determining inventory costs is used consistently from year to year. Allowance for inventory obsolescence is provided when the market value of certain inventory items are lower than the cost.

Valuation of Long-lived Assets - The carrying values of the Company's long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that they may not be recoverable. Should such an event occur, the Company would project undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of the long-lived asset will not be recovered, the carrying value is reduced by the estimated excess of the carrying value over the projected discounted cash flows.

Property and Equipment - Property and equipment are stated at cost. Maintenance and repairs are charged to expense as incurred and major improvements are

F-8

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

capitalized. Gains or losses on sales or retirements are included in the statement of operations in the period of disposition.

Intangible Assets - Acquisition costs on patents, trademarks, licenses, techniques, formulas and other intangibles are capitalized and amortized using the straight-line method over their useful lives. For those intangible assets, such as patents, with legal protection over a period, their useful life is the protected period. Others that do not have legal protection periods are amortized generally over 5 to 10 years. The Company does not capitalize internally generated intangible assets. The Company's intangible assets consist of techniques for medicines.

Advances to Suppliers and Advances from Customers - The Company, as is the common practice in the PRC, will often pay advanced payments to suppliers for materials and receive from customers advances for finished products. As of December 31, 2006 and 2005, the advances to suppliers were \$2,255,877 and \$2,123,729, respectively, and the advances from customers were \$141,871 and \$50,755, respectively.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Revenue Recognition - The Company recognizes revenue when it is realized and earned. The Company considers revenue realized or realizable and earned when (1) it has persuasive evidence of an arrangement, (2) delivery has occurred, (3) the sales price is fixed or determinable, and (4) collectibility is reasonably assured. Delivery does not occur until products have been shipped to the client, risk of loss has transferred to the client and client acceptance has been obtained, client acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in client acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.

Cost of Revenues - Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of product.

Research and Development - Research and development expenditures are recorded as expenses in the period in which they occur.

Retirement Benefit Plans - The Company contributes to various employee retirement benefit plans organized by provincial governments under which it is required to make monthly contributions to these plans at rates prescribed by the related provincial governments. The provincial governments undertake to assume the retirement benefit obligations of all existing and future retired employees of the Company. Contributions to these plans are charged to expense as incurred.

Advertising Costs - Advertising costs are expensed when incurred.

Basic and Diluted Earnings per Common Share - Basic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding. Diluted earnings per common share are calculated to give effect to potentially issuable dilutive common shares. There were no potentially issuable common shares outstanding at December 31, 2005 and 2006.

F-9

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

Credit risk - The carrying amounts of accounts receivable included in the balance sheet represent the Company's exposure to credit risk in relation to its financial assets. No other financial assets carry a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. It maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded management's estimations.

Interest rate risk - The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.

New Accounting Standards - In December 2004, FASB issued Statements of Financial Accounting Standards (SFAS) 123R, "Share-Based Payment" (SFAS 123R). SFAS No. 123R revises FASB Statement No. 123, "Accounting for Stock-Based Compensation," and supersedes APB Opinion No. 25, "Accounting for Stock Issued to Employees." SFAS 123R focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions. SFAS 123R requires companies to recognize in the statement of operations the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value of such awards (with limited exceptions). SFAS 123R is effective as of the first reporting period beginning after December 15, 2005. The Company has not yet quantified the effects of the adoption of SFAS 123R, but

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

it is expected that the new standard will result in significant stock-based compensation expense. The pro forma effects on net loss and loss per share if the Company had applied the fair value recognition provisions of the original SFAS 123R on stock compensation awards (rather than applying the intrinsic value measurement provisions of APB 25) are disclosed above in stock-based compensation. Although such pro forma effects of applying the original SFAS 123 may be indicative of the effects of adopting SFAS 123R, these provisions differ in some important respects.

In December 2004, the FASB issued SFAS Statement No. 153, "Exchanges of Non-monetary Assets—an amendment of APB Opinion No. 29" (SFAS 153). The Company adopted the provisions of SFAS 153 in January 2006. The adoption of SFAS 153 did not have a material impact on the Company's consolidated financial statements.

In May, 2005, the FASB issued SFAS No. 154, "Accounting Changes and Errors Corrections—an amendment to APB Opinion No. 20 and Statement of Financial Accounting Standards No. 3" (SFAS 154). The Company adopted the provisions of SFAS 154 in January 2006. The adoption of SFAS 154 did not have a material impact on the Company's consolidated financial statements.

In February 2006, the FASB issued SFAS No. 155, Accounting for Certain Hybrid Financial Instruments -- an amendment of FASB Statements No. 133 and 140 (SFAS155). SFAS155 eliminates the prohibition on a qualifying special-purpose entity from holding a derivative financial instrument that pertains to a beneficial interest other than another derivative financial instrument. SFAS 155

F-10

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

is effective for the Company for all financial instruments acquired or issued beginning January 1, 2007. The impact of SFAS No. 155 will depend on the nature and extent of any new derivative instruments entered into after the effective date.

In March 2006, the FASB issued SFAS No. 156, Accounting for Servicing of Financial Assets - an amendment of FASB Statement No. 140 (SFAS 156). SFAS 156 amends SFAS 140 requires an entity to recognize a servicing asset or servicing liability each time it undertakes an obligation to service a financial asset. It also requires all separately recognized servicing assets and servicing liabilities to be initially measured at fair value, if practicable. SFAS 156 permits an entity to use either the amortization method or the fair value measurement method for each class of separately recognized servicing assets and servicing liabilities. SFAS 156 is effective for the Company as of January 1, 2007. The impact of adoption of this statement on the Company's consolidated financial statements, if any, has not yet been determined.

In July 2006, the FASB issued Interpretation No. 48, "Accounting for Uncertainty in Income Taxes" (FIN 48), which attempts to set out a consistent framework for preparers to use to determine the appropriate level of tax reserves to maintain for uncertain tax positions. This interpretation of FASB Statement No. 109 uses a two-step approach wherein a tax benefit is recognized if a position is more-likely-than-not to be sustained. The amount of the benefit is then measured to be the highest tax benefit which is greater than fifty percent likely to be realized. FIN 48 also sets out disclosure requirements to enhance transparency of an entity's tax reserves. The Company will be required to adopt this Interpretation as of January 1, 2007. The Company is still evaluating the impact of the adoption of FIN 48.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

In September 2006, the FASB issued Statement of Financial Accounting Standards No.157, "Fair Value Measurements" (SFAS 157), which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and requires additional disclosures about fair value measurements. SFAS 157 aims to improve the consistency and comparability of fair value measurements by creating a single definition of fair value. The Statement emphasizes that fair value is not entity-specific, but instead is a market-based measurement of an asset or liability. SFAS 157 upholds the requirements of previously issued pronouncements concerning fair value measurements and expands the required disclosures. This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, however earlier application is permitted provided the reporting entity has not yet issued financial statements for that fiscal year. The Company does not believe that the adoption of SFAS 157 will have a material effect on its consolidated financial statements.

In September 2006, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 108 (SAB 108). SAB 108 was issued to provide interpretive guidance on how the effects of the carryover reversal of prior year misstatements should be considered in quantifying a current year misstatement. The provisions of SAB 108 are effective for the Company for its December 31, 2006 year-end. The adoption of SAB 108 had no impact on the Company's consolidated financial statements.

F-11

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities", including an amendment of FASB Statement No. 115 SFAS 159. This pronouncement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. The impact of adopting SFAS 159 on the Company's consolidated financial statements, if any, has not yet been determined.

NOTE 2 - ACQUISITION

On May 25, 2005, the Company entered into an agreement with the shareholders of Helpson, in which the Company agreed to acquire, and the shareholders of Helpson agreed to sell, all of the outstanding shares of Helpson in exchange for the assumption of obligations to make cash payments to the Helpson shareholders in the form of common stock dividends from Helpson of \$4,154,041, the assumption of \$4,646,409 of other liabilities and the issuance of non-interest bearing promissory notes totaling \$3,413,265 payable three months after Helpson obtained a business license in the PRC as a wholly foreign owned entity. Helpson obtained such license on June 16, 2005 and the shares of Helpson were transferred to the Company on that date. Since June 16, 2005 was recognized as the date of the acquisition, the promissory notes became due September 16, 2005.

Since Helpson is an operating company and control of Helpson changed upon the closing of the acquisition agreement, the Company is the accounting acquirer and has recognized the acquisition of Helpson as a business combination in

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

accordance with Statements of Financial Accounting Standards No. 141, Business Combinations. On April 25, 2005, Helpson declared a dividend to the selling shareholders of \$4,154,041 which equaled Helpson's retained earnings at March 31, 2005 less deferred income tax assets of \$86,985 that are not considered part of distributable profits under PRC law. The fair value of the net assets of Helpson was determined by appraisal and exceeded the purchase price of the net assets acquired. That excess was allocated as a pro rata reduction of the amounts that otherwise would have been assigned to the non-current assets acquired.

At June 16, 2005, the purchase price was allocated to the assets acquired and liabilities assumed as follows:

F-12

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

Current assets	\$ 9,570,918
Property and equipment	2,555,565
Intangible	71,210

Total Assets Acquired	12,197,693

Current liabilities	7,864,066
Long-term liabilities	1,005,694

Total Liabilities Assumed	8,869,760

Net Assets Acquired	\$ 3,327,933
	=====

Intangible assets consist of registered patents, trademarks, licenses, techniques and formulas related to several Western and Chinese medicines, biochemical products, health products, and cosmetics. These intangible assets have a weighted-average useful life of approximately 5 years.

The following pro forma information is presented to reflect the operations of the Company for the year ended December 31, 2005, as though the acquisition of Helpson had been completed on January 12, 2005, and the operations of the Company and Helpson are combined for the entire year. The pro forma information is only illustrative of the effects of the acquisition and does not necessarily reflect the results of operations that would have resulted had the acquisition actually occurred on that date.

For the Year Ended
December 31, 2005
(proforma)

(unaudited)

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Revenue	\$ 14,075,521
Net Income	5,778,901

Basic and diluted earnings per common share	\$ 0.17
	=====

Pro forma net income for the twelve months ended December 31, 2005 includes nonrecurring interest expense of \$85,332 resulting from the amortization of the discount on the \$3,413,265 promissory notes payable to the former Helpson shareholders, which discount was computed based upon an imputed interest rate of 10% per annum.

The reorganization was recognized as a stock split of the common stock of Onny and the effective issuance by Onny of the 2,500,060 shares of common stock of the Company that remained outstanding in exchange for the assumption of \$4,473 of liabilities. The acquisition of the Company was recognized as a non-monetary exchange.

NOTE 3 - INVENTORY

F-13

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

Inventory consisted of the following at December 31, 2006 and 2005:

	December 31,	
	2006	2005
	-----	-----
Raw materials	\$ 8,458,210	\$ 4,673,352
Work in progress	1,679,952	819,146
Finished goods	139,725	292,698
	-----	-----
Total Inventory	\$ 10,277,887	\$ 5,785,196
	=====	=====

NOTE 4 - PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at December 31, 2006 and 2005:

	December 31,	
	2006	2005
	-----	-----
Permit of land use	\$ 360,304	\$ 348,884
Building	1,640,629	1,123,144
Plant, machinery and equipment	1,253,572	1,120,289
Motor vehicle	14,763	14,295
Office equipment	75,550	62,211
Construction in progress	-	389,703

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Total	3,344,818	3,058,526
Less: accumulated depreciation	(619,645)	(250,184)
Property and Equipment, net	\$ 2,725,173	\$ 2,808,342

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

Asset	Life - years
Permit of land use	40 - 70
Building	20 - 35
Plant, machinery and equipment	10
Motor vehicle	5 - 10
Office equipment	5

For the year ended December 31, 2006, depreciation expense was \$353,831. For the period from January 12, 2005 (Date of Inception) through December 31, 2005 depreciation expense was \$213,696.

NOTE 5 - INTANGIBLE ASSETS

Intangible assets represent the costs on patents, trademarks, licenses, techniques and formulas. Intangible assets have a weighted-average remaining useful life of approximately three years. Amortization of intangible assets was

F-14

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

\$43,170 for the year ended December 31, 2006, and \$36,488 for the period from January 12, 2005 through December 31, 2005.

The estimated aggregate amortization expense for the next three years follows:

Year	Amount
2007	\$ 27,869
2008	19,200
2009	18,275
Total	\$ 65,344

NOTE 6 - DEBT

During 2006, the Company borrowed approximately \$2,174,608 from the Communication Bank of China in three installments. The first two installments totaled approximately \$1,535,018 and were borrowed in July 2006 at a interest rate of 6.1425%. The final installment was for approximately \$639,591 and was

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

borrowed in August 2006 at a rate of 6.4260%. The loan is due in one year from borrowing and is collateralized with equipment and machinery valued at \$4,657,400. At December 31, 2006 the company also had a note payable due to the former shareholders of Helpson, see Note 10. The value of the note at year end was \$4,359,041.

NOTE 7 - INCOME TAXES

The Company accounts for its income taxes in accordance with Statement of Financial Accounting Standards ("SFAS") No. 109, which requires recognition of deferred tax assets and liabilities and their respective tax bases and any tax credit carry forwards available. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

According to federal law in the Peoples Republic of China (PRC), enterprises with foreign investment and foreign enterprises doing business in the PRC are generally subject to federal enterprise income tax at a rate of 30%. Effective at the beginning of 2006 and extending through 2007, Peoples Republic of China granted the company a "tax holiday" that allows the Company to be exempt from income taxes for the first two profitable years. This "tax holiday" further allows the Company to be exempt from 50% of income taxes during the third through the fifth years. The reduced tax rate for 2008 through 2010 is 15%. Additionally, Hainan province is considered a 'developing economic region' which has a reduced statutory tax rate of 15%, which results in a tax holiday rate of 7.5% during the third through the fifth years of profitability.

Following is a reconciliation of income taxes calculated at the United States' federal statutory rates to actual income tax expense:

F-15

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

	December 31,	
	2006	2005
Tax at US Federal statutory rates (34%)	\$ 2,919,609	\$ 1,377,561
Non-deductible expenses	27,559	137,458
Change in temporary differences	(22,654)	(114,254)
Effect of lower foreign tax rates	(2,924,514)	(1,148,664)
Income tax provision	\$ -	\$ 252,101

The company has a deferred tax asset based upon the temporary differences from the allowance for bad debt that equaled \$540,604 at December 31, 2006 and \$130,458 at December 31, 2005. The Company has also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

NOTE 8 - STOCKHOLDERS' EQUITY

On April 12, 2005, Onny was incorporated and issued 85,112 shares for \$1. On August 16, 2005, the shareholder of Onny made capital investments of cash into Onny of \$3,491,174 in exchange for the issuance of 25,193,273 shares of common stock. On October 19, 2005 Onny issued shares of convertible preferred stock for \$4,313,000 (net of offering costs of \$687,000). In conjunction with the reorganization of Onny into the Company, which also occurred on October 19, 2005, these preferred shares were converted into 6,944,611 shares of common stock. The reorganization of Onny into the Company on October 19, 2005, is reflected in these consolidated financial statements by the issuance of 2,500,060 shares of common stock and the assumption of \$4,473 of liabilities. See Note 2. In 2006, the stockholders approved increasing the shares of common stock authorized by 30,000,000 shares for a total of 60,000,000 shares authorized.

NOTE 9 - COMMITMENTS AND CONTINGENCIES

Economic environment - Significantly all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with entities operating in the United States of America. These risks include, among others, the political, economic and legal environments and foreign currency exchange. The Company's results may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

In addition, all of the Company's revenue is denominated in the PRC's currency, CNY, which must be converted into other currencies before remittance out of the PRC. Both the conversion of CNY into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

F-16

China Pharma Holdings, Inc.
Notes to the Consolidated Financial Statements
December 31, 2006 & 2005

NOTE 10 - RELATED PARTY TRANSACTIONS

Dividends payable - The terms of a \$4,154,041 dividend declared on April 25, 2005 require that if such dividend had not been paid by December 31, 2005, it should be transferred and reflected as a loan payable accruing interest at 2.25% per year to the former shareholders of Helpson. Inasmuch as the dividend was not paid by December 31, 2005 and has still not been paid, this amount is reflected on the accompanying consolidated financial statements as a current liability (adjusted for foreign currency translations as of the balance sheet dates) and is due upon demand.

NOTE 11 - CONCENTRATIONS

For the year ended December 31, 2006, three customers accounted for 17%, 11% and 10% of sales, respectively. In 2005, four customers accounted for 20%, 16%, 14% and 14% of sales, respectively. In addition, two customers made up 18% and 14% of accounts receivable in 2006 and two customers made up 19% and 14% of accounts receivable in 2005. Finally, purchases from two suppliers accounted for 44% and 34% of raw material purchases in the year ended December 31, 2006 and 46% and 42% of raw material purchases in the year ended December 31, 2005.

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

NOTE 12 - SUBSEQUENT EVENT

On February 1, 2007, the Company completed an offering of Units priced at \$1.70 per Unit consisting of one share of Company common stock and a warrant to purchase one-half of a share of Company common stock at an exercise price of \$2.38 per share. The Company received gross proceeds in the aggregate amount of \$4,259,900. The net proceeds, after deduction of related offering expenses of \$445,258, amounted to \$3,814,642. The Company issued an aggregate of 2,505,882 shares of common stock and issued three-year warrants to purchase an aggregate of 1,252,941 shares of Company's common stock to 17 accredited investors. The proceeds were allocated to the warrants based upon their fair value or \$2,010,219, and the balance of the proceeds was allocated to the shares of common stock. The fair value of the warrants, determined using the Black-Scholes Option Pricing Model, was calculated using the following assumptions: risk free interest rate of 4.80%, expected dividend yield of 0%, expected volatility of 124.39% and an expected life of 3 years.

The common shares and the shares underlying the warrants have registration rights, and the Company is required to file a registration statement including said shares with the Securities and Exchange Commission. In the event that the Company does not file a registration statement within 60 days of the completion of the offering, the Company will be required to pay a penalty to each investor equal to one percent (1%) of the purchase price of the common stock and the warrants and an additional one percent (1%) for each additional 30-day period during which such registration statement is not filed. The Company estimates that the probability of not filing the registration statement within the allowed time period is remote; therefore no accrual has been made for these potential penalties.

F-17

PART II: INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 24. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities (including reimbursement for expenses incurred) arising under the Securities Act.

Our Amended and Restated Certificate of Incorporation and our Bylaws provide for the indemnification of a present or former director or officer. Such indemnification shall include expenses, including attorney's fees actually or reasonably incurred by him. We may indemnify such individuals against all costs, expenses, and liabilities incurred in a threatened, pending, or completed action, suit, or proceeding brought because such individual is one of our directors or officers.

ITEM 25. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.

The following table sets forth an itemization of various expenses, all of which we will pay in connection with the sale and distribution of the securities being registered. All of the amounts shown are estimates, except the SEC registration fee.

SEC Registration Fee	\$	207.71
Accounting Fees and Expenses	\$	25,000.00

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

Legal Fees and Expenses	\$ 30,000.00
Miscellaneous	\$ 2,385.00
Total	\$ 57,592.71

ITEM 26. RECENT SALES OF UNREGISTERED SECURITIES.

On May 11, 2005, we sold to Halter Financial Group, Inc. ("HFG") in a private placement 1,875,045 shares of restricted common stock at a purchase price of \$0.1066641 per share, pursuant to the terms of a Stock Purchase Agreement (the "Purchase Agreement") executed by the parties on said date. As a result of the purchase, HFG became our controlling shareholder, owning approximately 75% of our issued and outstanding shares of common stock. This issuance was made in reliance on Section 4(2) of the Act and was made without general solicitation or advertising. The purchaser was a sophisticated investor with access to all relevant information necessary to evaluate the investment, and who represented to us that the shares were being acquired for investment.

On October 19, 2005, we entered into a Securities Exchange Agreement with Onny and its original stockholders pursuant to which we acquired all of the issued and outstanding shares of Onny from said stockholders in exchange for 27,499,940 shares of our common stock. This issuance was made in reliance on Section 4(2) of the Act and was made without general solicitation or advertising. The acquirers were sophisticated investors with access to all relevant information necessary to evaluate the investment, and who represented to us that the shares were being acquired for investment.

60

On February 1, 2007, the Company completed an offering of Units priced at \$1.70 per Unit consisting of one share of Company common stock and a warrant to purchase one-half of a share of Company common stock at an exercise price of \$2.38 per share. The Company issued an aggregate of 2,505,882 shares of common stock and issued three-year warrants to purchase an aggregate of 1,252,941 shares of Company's common stock to 17 accredited investors. This issuance was made in reliance on Section 4(2) of the Act and was made without general solicitation or advertising. The acquirers were sophisticated investors with access to all relevant information necessary to evaluate the investment, and who represented to us that the shares were being acquired for investment.

ITEM 27. EXHIBITS

The following Exhibits are attached hereto or incorporated herein by reference.

Exhibit No.	Description
2.1	Securities Exchange Agreement by and among Onny Investment Limited dated October 19, 2005. (3)
3.1	Memorandum and Articles of Association. (4)
3.2	Articles of Association of Helpson Medical Biotechnology Co. (3)
5.1	Opinion regarding legality (8)

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

10.1	Stock Purchase Agreement by and among Halter Financial Group Inc. dated May 11, 2005 filed on May 11, 2005. (1)
10.2	Subscription Agreement by and among Onny Investment Limited stockholders. (3)
10.3	Employment Contract by and among Zhilin LI dated July 1, 2005. (5)
10.4	Employment Contract by and among Xinhua WU dated July 1, 2005. (5)
10.5	Employment Contract by and among Jian YANG dated July 1, 2005 (5)
10.6	Subscription and Registration Rights Agreement among China Pharma and 17 investors (6)
10.7	Form of Warrant (6)
10.8	Supply Agreement entered into by Hainan Helpson Medicine and Bio-Technology Co. Ltd. and Sichuang Chengxin Pharmaceutical Company (7)
10.9	Supply Agreement entered into by Hainan Helpson Medicine and Bio-Technology Co. Ltd. and Hainan Xinxin Biotechnology Company (7)
10.10	Sales Contract entered into by Hainan Helpson Medicine and Bio-Technology Co. Ltd. and Hainna Xinglin Medicine company (7)
10.11	Supply Agreement entered into by Hainan Helpson Medicine and Bio-Technology Co. Ltd. and Hainan Liang Bishi huangzhuang pin company (7)
16.1	Letter regarding Change in certifying Accountant dated August 15. (2)
21	Subsidiaries of China Pharma Holdings, Inc. filed on October 20, 2005. (4)

61

23.1	Consent of King and Wood (Included in Exhibit 5.1) (8)
23.2*	Consent of Hansen, Barnett & Maxwell, P.C.

*Filed herewithin

- (1) Previously filed as an exhibit to our report on Form 8-K (Commission File Number: 000-29523) filed with the Commission on May 11, 2005.
- (2) Previously filed as an exhibit to our report on Form 8-K (Commission File Number: 000-29523) filed with the Commission on August 18, 2005.
- (3) Previously filed as an exhibit to our report on Form SB-2 (Commission File

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

- Number: 333-129161) filed with the Commission on October 20, 2005.
- (4) Previously filed as an exhibit to our report on Form SB-2 (Commission File Number: 333-129161) filed with the Commission on December 23, 2005.
 - (5) Previously filed as an exhibit to our report on Form 10-QSB (Commission File Number: 000-29523) filed with the Commission on November 16, 2006.
 - (6) Previously filed as an exhibit to our report on Form 8-K (Commission File Number: 000-29523) filed with the Commission on February 6, 2007.
 - (7) Previously filed as an exhibit to our report on Form 10-KSB (Commission File Number: 000-29523) filed with the Commission on March 28, 2007.
 - (8) Previously filed as an exhibit to our report on Form SB-2 (Commission File Number: 333-141734) filed with the Commission on March 30, 2007.

ITEM 28. UNDERTAKINGS

(a) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions described under Item 14 above, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

(b) The undersigned registrant hereby undertakes:

(i) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement; (i) To include any Prospectus required by section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the Prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually, or in the aggregate, represents a fundamental change in the information set forth in the Registration Statement; notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the

estimated maximum offering range may be reflected in the form of Prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the Offering.

(c) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

63

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Haikou, on April 3, 2007.

China Pharma Holdings, Inc.

By: /s/ Zhilin Li

Zhilin Li
Chief Executive Officer,
President and Director

By: /s/ Xinhua Wu

Xinhua Wu
Chief Financial Officer and Director

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

SIGNATURE	TITLE	DATE
/s/ Zhilin Li ----- Zhilin Li	President , Chief Executive Officer and Director	April 3, 2007
/s/ Xinhua Wu	Chief Financial Officer and	April 3, 2007

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form SB-2/A

----- Director
Xinhua Wu

/s/ Heung Mei Tsui Director April 3, 2007

Heung Mei Tsui
